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1.1	  Liver	  Function	  and	  Structure:	  
	   The	   anatomy	   and	   physiology	   of	   the	   liver	   have	   been	   extensively	   studied	   and	   are	   well	  
understood.	  The	  following	  overview	  is	  adapted	  from	  Casarett	  and	  Doull’s	  Toxicology:	  The	  Basic	  




	   The	   liver’s	   positioning	   between	   the	   intestines	   and	   the	   rest	   of	   the	   body	   allows	   it	   to	  
effectively	  maintain	  metabolic	  homeostasis	  by	  metabolizing,	  detoxifying	  and	  excreting	  ingested	  
nutrients,	   xenobiotics	   and	  environmental	   toxicants.	   These	   foreign	   compounds	  are	  brought	   to	  
the	   liver,	   via	   the	  portal	   vein,	   following	  absorption	   in	   the	   stomach	  or	   intestine.	  Along	  with	   its	  
major	  role	  in	  regulating	  metabolic	  homeostasis,	  the	  liver	  is	  also	  responsible	  for	  the	  synthesis	  of	  
plasma	  proteins,	  such	  as	  albumin,	  the	  synthesis	  and	  secretion	  of	  bile	  and	  cholesterol,	  and	  the	  
metabolism	  of	  fats.	  
	  
	  Liver	  Anatomy:	  
In	   humans,	   the	   liver	   is	   a	   four	   lobed	   structure	   covered	   by	   a	   thin	   layer	   of	   connective	  
tissue,	  known	  as	  Glisson’s	  capsule.	  The	  liver	  is	  composed	  of	  various	  cell	  types,	  which	  consist	  of	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hepatocytes	  and	   the	   cells	  of	   the	   sinusoid.	  Hepatocytes	  are	   the	  parenchymal	   cells	  of	   the	   liver	  
and	  make	  up	  60%	  of	   the	  cell	  population,	  as	  well	  as	  80%	  of	   the	  volume	  of	   the	   liver.	  They	  are	  
large	   cells	  with	   large	   amounts	   of	  mitochondria	   and	   endoplasmic	   reticulum	   and	   round	   nuclei	  
containing	  peripherally	  dispersed	  chromatin.	  Hepatocellular	  nuclei	  vary	  in	  size	  and	  can	  often	  be	  
binucleated.	   The	   hepatocytes	   are	   organized	   in	   a	   three-­‐dimensional	   lattice	   where	   the	   spaces	  
between	   cords	   of	   hepatocytes	   consist	   of	   the	   sinusoids,	   which	   act	   as	   the	   hepatocyte	   blood	  
supply.	   Sinusoids	   consist	   mainly	   of	   endothelial	   cells,	   but	   also	   contain	   stellate	   cells	   (act	   in	  
storage	   of	   vitamin	   A	   and	   synthesis	   of	   extracellular	   matrix	   proteins),	   Kupffer	   cells	   (resident	  
macrophages	  of	  the	  liver),	  lymphocytes,	  and	  natural	  killer	  cells.	  	  
There	   are	   two	  ways	   in	  which	   the	   liver	   can	   be	   structurally	   organized,	   these	   being	   the	  
lobule	   and	   the	   acinus.	   The	   lobular	   classification	   organizes	   the	   liver	   into	   hexagonal	   lobules	  
around	  a	  central	  vein.	  At	  each	  of	  the	  six	  corners	  of	  the	  hexagon	  are	  portal	  triads,	  consisting	  of	  a	  
portal	  vein,	  hepatic	  arteriole	  and	  bile	  duct.	  Blood	  entering	  the	  liver	  through	  both	  the	  portal	  vein	  
and	  hepatic	  arteriole	  mix	  together	  before	  entering	  the	  sinusoids	  making	  its	  way	  to	  the	  central	  
vein,	   where	   it	   exits	   the	   liver.	   The	   lobular	   structure	   consists	   of	   three	   zones	   (centrilobular,	  
midzonal	  and	  periportal),	  which	  are	  often	  used	  in	  the	  description	  of	  pathological	  parenchymal	  
lesions.	  	  
The	  acinar	  classification	  better	  depicts	  a	  functional	  hepatic	  unit.	  The	  acinus	  is	  diamond	  
shaped	  and	   is	  centered	  on	  the	  terminal	  branches	  of	  the	  portal	  vein	  and	  hepatic	  artery.	  There	  
are	  three	  zones	  of	  decreasing	  blood	  oxygen	  concentrations	  moving	  away	  from	  the	  portal	  blood	  
vessels	  towards	  the	  central	  vein.	  Zone	  1	  is	  closest	  to	  the	  blood	  supply	  and	  contains	  blood	  with	  
the	  highest	  oxygen	  content,	  zone	  3	  is	  closest	  to	  the	  central	  vein	  and	  blood	  is	  most	  depleted	  of	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oxygen	  and	  zone	  2	  is	  located	  between	  the	  two.	  	  Due	  to	  the	  higher	  level	  of	  oxygen,	  hepatocytes	  
in	   zone	   1	   are	   mitochondria-­‐rich	   and	   are	   the	   most	   involved	   in	   fatty	   acid	   oxidation	   and	  
gluconeogenesis.	   There	   is	   also	   a	   gradient	   of	   proteins	   and	   enzymes	   involved	   in	   xenobiotic	  
metabolism	   and	   detoxification.	   Hepatocytes	   in	   zone	   1	   have	   higher	   concentrations	   of	   the	  
antioxidant	   glutathione,	   whereas	   hepatocytes	   in	   zone	   3	   contain	   the	   bulk	   of	   the	   metabolic	  




	   Nuclear	  factor	  erythroid	  2-­‐related	  factor	  2	  (Nrf2)	  is	  a	  transcription	  factor	  that	  acts	  in	  the	  
activation	  and	  regulation	  of	  the	  cellular	  response	  to	  oxidative	  stress.	  It	  does	  this	  by	  inducing	  the	  
transcription	  of	   a	   series	  of	   antioxidant-­‐related	  genes,	  which	  allows	   it	   to	   regulate	   cell	   survival	  
and	  defense	   (Jaramillo	   and	  Zhang,	   2013).	  Nrf2	  was	   first	   isolated	  during	   a	   screen	   for	  proteins	  
that	  bind	  the	  locus	  control	  region	  (LCR)	  located	  at	  the	  5’	  end	  of	  the	  β-­‐globin	  gene	  cluster	  (Moi	  
et	  al.,	  1994).	  The	  β-­‐globin	  gene	  cluster	  on	  chromosome	  11	  consists	  of	  five	  genes,	  which	  encode	  
for	   components	  of	   the	  globulin	   family	  of	  proteins,	   such	  as	  hemoglobin	   (Levings	  and	  Bungert,	  
2002).	   The	   LCR	   is	   a	   regulatory	   element	   in	   the	   β-­‐globin	   locus	   containing	   four	   sites	   that	   are	  
hypersensitive	   to	   DNAse	   I.	   These	   four	   hypersensitive	   sites	   (HS)	   serve	   as	   binding	   sites	   for	  
transcription	   factors,	   such	   as	   GATA	   binding	   protein	   1	   (GATA-­‐1;	   regulator	   of	   blood	   cell	  
differentiation	   in	   erythroid	   cells),	   Erythroid	   Krüppel-­‐like	   factor	   (EKLF;	   erythroid	   transcription	  
factor	   needed	   for	   human	   β	   -­‐globin	   gene	   expression)	   and	   NF-­‐E2	   (nuclear	   factor	   erythroid	   2)	  
(Levings	  and	  Bungert,	  2002).	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   From	  the	  LCR	  binding	  assay	  it	  was	  found	  that	  the	  protein	  now	  known	  as	  Nrf2	  binds	  to	  
the	   same	  hypersensitive	   site	   (HS2)	   as	  NF-­‐E2.	  Nrf2	   and	  NF-­‐E2	  were	   found	   to	  be	   a	  part	   of	   the	  
same	   family	   of	   cap	   ‘n’	   collar	   basic	   leucine	   zipper	   (bZIP)	   transcription	   factors	   and	  both	   act	   as	  
strong	  activators	  of	  RNA	  polymerase	  II	  (Moi	  et	  al.,	  1994).	  There	  is,	  however,	  a	  difference	  in	  the	  
expression	  levels	  of	  the	  two	  genes.	  NF-­‐E2	  is	  mainly	  expressed	  in	  erythroid	  cells,	  whereas	  Nrf2	  is	  
ubiquitously	  expressed	  at	  low	  levels.	  The	  highest	  levels	  of	  Nrf2	  can	  be	  found	  in	  the	  liver,	  kidney	  
and	  lung	  (Chan	  et	  al.,	  1996).	  	  
	  
Regulation:	  
	   In	  normal	   cellular	   conditions	  Nrf2	   is	   sequestered	   in	   the	  cytoplasm	  by	   the	  E3	  ubiquitin	  
ligase	   Kelch-­‐like	   ECH-­‐associated	   protein	   1	   (Keap1).	   E3	   ubiquitin	   ligases	   act	   to	   catalyze	   the	  
isopeptide	  binding	  of	  ubiquitin	  to	  target	  proteins,	  thus	  targeting	  these	  proteins	  for	  proteasomal	  
degradation	   (Kobayashi	   et	   al.,	   2004).	   Sequestration	   of	   Nrf2	   occurs	   through	   an	   association	  
between	  the	  Nrf2-­‐ECH	  homology	  (NEH)	  2	  domain	  and	  the	  Keap	  1	  double	  glycine	  repeat	  (DGR)	  
region,	  located	  at	  the	  C-­‐terminal	  domain	  of	  the	  protein	  (Itoh	  et	  al.,	  1999).	  Interactions	  between	  
the	  intervening	  region	  (IVR)	  domain	  of	  Keap1	  and	  the	  Cul3-­‐type	  E3	  ligase	  complex	  then	  act	   in	  
the	  ubiquitination	  of	  Nrf2	  and	  promote	  its	  subsequent	  degradation.	  
	   In	  the	  presence	  of	  electrophiles,	  the	  repression	  of	  Nrf2	  by	  Keap1	  is	  inhibited	  and	  newly	  
synthesized	   Nrf2	   is	   able	   to	   translocate	   to	   the	   nucleus,	   where	   it	   can	   bind	   to	   the	   antioxidant	  
response	  element	  (ARE)	  of	  target	  genes	  and	  mediate	  transcription	  of	  these	  genes	  (Watai	  et	  al.,	  
2007).	   The	   exact	   mechanism	   of	   how	   electrophiles	   disrupt	   the	   repression	   is	   still	   unclear,	  
however,	  it	  is	  known	  that	  the	  electrophile	  acts	  to	  prevent	  Keap1-­‐mediated	  ubiquitination,	  and	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subsequent	  degradation	  of	  Nrf2.	   Five	  models	  have	  been	  proposed	   to	  explain	   the	  mechanism	  
behind	  the	  loss	  of	  Nrf2	  repression.	  A	  Hinge	  and	  Latch	  model	  suggests	  that	  cysteine	  residues	  on	  
Keap1	   are	  modified	   by	   electrophiles,	   causing	   a	   disruption	   of	   the	   Keap1-­‐Cul3	   complex	   and	   a	  
preventing	   Nrf2	   ubiquitination	   (Tong	   et	   al.,	   2006).	   Another	   postulate	   suggests	   that	   a	   Cul1	  
interference	   factor,	   cullin	   associated	   and	   neddylation	   dissociated	   1	   (CAND1),	   disrupts	   the	  
Keap1-­‐Cul3	   complex.	   A	   third	   model	   suggests	   that	   oxidative	   stress	   promotes	   Keap1	   self-­‐
ubiquitination	   and	   degradation.	   The	   other	   two	   mechanisms	   suggest	   disruption	   of	   a	   nuclear	  
export	   signal,	   either	   on	   Keap1	   or	   Nrf2,	   that	   senses	   oxidative	   stress	   and	   promotes	   nuclear	  
accumulation	  of	  either	  the	  Keap1-­‐Nrf2	  complex	  or	  just	  Nrf2,	  respectively	  (Watai	  et	  al.,	  2007).	  	  
	  
Antioxidant	  Response:	  
	   Nrf2	  acts	  in	  the	  cell’s	  response	  to	  oxidative	  stress	  by	  binding	  the	  ARE	  and	  regulating	  the	  
transcription	  of	  genes	  involved	  in	  various	  antioxidant	  pathways.	  	  	  
Nrf2	  controls	   the	  production	  of	   the	  antioxidant	  cofactor	  glutathione	  (GSH),	  which	  acts	  
to	   scavenge	   free	   radicals	   in	   the	   cell.	   Nrf2	   regulates	   the	   transcription	   of	   the	   two	   subunits	   of	  
glutamate-­‐cysteine	   ligase	   (Gcl),	  mainly	   Gclm	   (modifying	   subunit)	   and	  Gclc	   (catalytic	   subunit).	  
Gcl	   catalyzes	   the	   rate-­‐limiting	  step	  of	  GSH	  synthesis	   (Gorrini	  et	  al.,	  2013).	  Nrf2	  also	   regulates	  
the	  expression	  of	  NAD(P)H:quinone	  oxidoreductase	  1	  (Nqo1),	  which	  is	  involved	  in	  the	  reduction	  
of	   quinones	   to	   hydroquinones.	   This	   prevents	   the	   formation	   of	   semiquinone	   radical	  
intermediates	  and	  reduces	  cellular	  oxidative	  stress	  (Atia	  et	  al.,	  2014).	  	  
Oxygen	   is	   required	   by	   aerobic	   organisms	   to	   generate	   energy	   in	   the	   form	   of	   ATP,	   but	  
oxygen	   can	  also	  be	   toxic.	  During	  normal	  metabolic	   function	  oxygen	   is	   converted	   into	   various	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oxygen	   free	   radicals	   and	   oxygen	   species	   that	   cause	   cellular	   oxidative	   damage.	   It	   has	   been	  
hypothesized	   that	   over	   time,	   oxidative	   stress	   builds	   up	   and	   causes	   a	   gradual	   reduction	   in	  
cellular	  function.	  In	  this	  oxidative	  stress	  theory	  of	  aging	  it	  is	  believed	  that	  the	  gradual	  reduction	  
in	  cellular	   function	  caused	  by	  oxidative	  stress	   is	  one	  explanation	  for	  the	  phenotype	  known	  as	  
aging	  (Harman,	  1956).	  Nrf2	  regulates	  a	  series	  of	  genes,	  such	  as	  superoxide	  dismutase	  (Sod)	  and	  
catalase	   (Cat),	   which	   function	   in	   the	   detoxification	   of	   damaging	   oxygen	   species	   that	   are	   key	  
contributors	  to	  aging	  (Zhang	  et	  al.,	  2015).	  Sod	  is	  a	  family	  of	  enzymes	  responsible	  for	  catalyzing	  
the	   dismutation	   reaction	   that	   converts	   superoxide	   anion	   radicals	   into	   oxygen	   and	   hydrogen	  
peroxide.	  Cat	   is	   then	  able	   to	   catalyze	   the	  detoxification	  of	  hydrogen	  peroxide	   to	  oxygen	  and	  
water	  (Zhang	  et	  al.,	  2015).	  	  
Nrf2	   is	   also	   involved	   in	   the	   regulation	   of	   pathways	   that	   indirectly	   causes	   decreased	  
oxidative	  stress.	  For	  example,	  Nrf2	  regulates	  the	  transcription	  of	  heme	  oxygenase	  1	  (Hmox1).	  
Hmox1	   catabolizes	   heme	   molecules	   to	   produce	   free	   iron	   (Fe(II)).	   Fe(II)	   is	   a	   cofactor	   in	   the	  
conversion	  of	  hydrogen	  peroxide	  to	  a	  very	  reactive	  hydroxyl	  radical	  and	  build	  up	  of	  Fe(II)	  in	  the	  
cell	   results	   in	   increased	   levels	   of	   oxidative	   stress	   through	   the	   production	   of	   this	   radical.	   The	  
increased	   formation	   of	   reactive	   oxygen	   species	   (ROS)	   is	   avoided	   by	   the	   detoxification	   and	  
sequestration	  of	  excess	  Fe(II)	   through	  the	  actions	  of	   the	   ferritin	  complex,	  whose	  subunits	  are	  
also	  regulated	  by	  Nrf2	  (Gorrini	  et	  al.,	  2013).	  
Another	   function	   of	   Nrf2	   is	   in	   the	   transcriptional	   regulation	   of	   transporters.	   These	  
include	   multidrug	   resistance-­‐associated	   protein	   2	   (Mrp2;	   Abcc2),	   multidrug	   resistance-­‐
associated	   protein	   3	   (Mrp3;	   Abcc3),	  multidrug	   resistance-­‐associated	   protein	   4	   (Mrp4;	   Abcc4)	  
and	  breast	  cancer	  resistance	  protein	  (Bcrp/Abcg2).	  The	  Mrps	  are	  members	  of	  the	  ATP-­‐binding	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cassette	   (ABC)	   family	   of	  ATP	  dependent	   efflux	   transporters.	  Mrp2	   is	  mainly	   expressed	   in	   the	  
hepatocyte	  cannalicular	  membrane	  and	  functions	  in	  the	  export	  of	  glucuronate,	  sulfate	  and	  GSH	  
conjugates	   into	   the	   bile	   for	   excretion	   (Jedlitschky	   et	   al.,	   2006).	   Mrp3	   is	   a	   basolateral	   efflux	  
transporter	   and	   acts	   as	   an	   alternate	   route	   for	   the	   export	   of	   bile	   acids	   and	   glucuronide	  
conjugates	   into	   portal	   circulation	   (Belinsky,	   2005).	   Mrp4	   is	   another	   basolateral	   efflux	  
transporter	  that	  acts	  to	  export	  bile	  acids	  and	  GSH	  conjugates.	  It	  also	  has	  a	  role	  in	  cell	  signaling	  
through	   regulation	   of	   intracellular	   levels	   of	   cyclic	   nucleotides,	   such	   as	   cAMP	   (Russel	   et	   al.,	  
2008).	   Bcrp	   is	   a	   canalicular	   efflux	   transporter	   and	   mediates	   the	   export	   of	   endogenous	  
compounds,	  such	  as	  urate	  and	  folate,	  as	  well	  as	  many	  xenobiotics	  into	  the	  bile	  (Eldasher	  et	  al.,	  
2013).	   The	   regulation	   of	   efflux	   transporters	   by	   Nrf2	   serves	   as	   a	   protective	   mechanism	   by	  
increasing	   the	   excretion	   of	   toxic	   compounds	   and	   decreasing	   cellular	   exposure	   to	   xenobiotics	  
with	  the	  potential	  to	  produce	  oxidative	  damage.	  	  
	  
1.3	  Ppar:	  
The	   peroxisome	   proliferator	   activated	   receptors	   (Ppars)	   consist	   of	   three	   transcription	  
factors	  (α,	  β/δ,	  and	  γ)	  that	  are	  part	  of	  the	  nuclear	  receptor	  superfamily.	  They	  heterodimerize	  
with	   retinoid	   X	   receptor	   (Rxr)	   and	   function	   in	   energy	  metabolism	   via	   the	   regulation	   of	   fatty	  
acids	  (FA)	  (Tyagi	  et	  al.,	  2011).	  Nuclear	  receptors	  share	  a	  well-­‐conserved	  structure	  that	  consists	  
of	   a	   DNA-­‐binding	   domain	   and	   ligand-­‐binding	   domain.	   The	   DNA-­‐binding	   domain	   of	   Ppars	  
recognize	  a	  six	  nucleotide	  direct	   repeat	   region	   in	   the	  promoter	  of	   target	  genes	  known	  as	   the	  
peroxisome	  proliferator	  response	  element	  (PPRE).	  The	  binding	  of	  a	  Ppar-­‐specific	   ligand	  allows	  
dissociation	   of	   the	   heterodimer	   from	   co-­‐repressor	   proteins	   and	   association	  with	   co-­‐activator	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proteins,	   such	   as	   Pparγ	   coactivator-­‐1α	   (PGC1α),	   that	   are	   necessary	   for	   the	   association	   of	   a	  
transcription-­‐initiation	   complex	   (Kersten,	  2014).	   The	   formation	  of	   the	   complex	   is	   followed	  by	  
association	  of	  the	  heterodimer	  complex	  with	  the	  PPRE	  of	  target	  genes	  and	  modulation	  of	  the	  
transcription	  of	  these	  genes.	  
	  
1.3.1	  Pparα:	  
Pparα	   is	  mainly	   expressed	   in	   the	   liver,	   however	   it	   is	   also	   expressed	   at	   lower	   levels	   in	  
skeletal	  muscle,	  heart	  and	  bone.	  It	  functions	  in	  the	  regulation	  of	  hepatic	  FA	  oxidation	  (Tyagi	  et	  
al.,	  2011)	  and	  also	  has	  protective	  functions	  in	  the	  antioxidant	  response	  (Manautou	  et	  al.,	  1994).	  
Activation	   of	   Pparα	   is	   also	   involved	   in	   repression	   of	   tissue	   inflammation,	   (i.e.	   vasculature,	  
spleen,	   liver).	   One	  mechanism	   explaining	   this	   effect	   is	   that	   Pparα	   activation	   antagonizes	   the	  
nuclear	   factor-­‐κB	   (NF-­‐κB)	   signaling	   pathway,	   which	   is	   involved	   in	   the	   immune	   response	   to	  
infection	  (Delerive,	  2001).	  Pparα	  is	  typically	  activated	  by	  FAs	  during	  periods	  of	  fasting,	  but	  can	  




	   Cloning	   of	   Pparα	   was	   first	   reported	   in	   1990	   following	   a	   screen	   of	   two	  murine	   cDNA	  
libraries	  using	  two	  isolated	  clones.	  From	  this	  screening,	  a	  468	  amino	  acid	  protein,	  now	  referred	  
to	  as	  Pparα,	  was	  identified	  (Issemann	  and	  Green,	  1990).	  The	  screen	  was	  conducted	  following	  a	  
study	  suggesting	  the	  presence	  of	  a	  peroxisome	  proliferator	  binding	  protein	  and	  another	  study	  
that	  showed	  the	  ability	  of	  peroxisome	  proliferators	  to	  rapidly	  alter	  the	  transcription	  of	  specific	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genes.	   Peroxisome	  proliferators	   are	   chemicals,	   such	   as	   the	   fibrate-­‐type	   class	   of	   drugs,	  which	  
cause	   hepatic	   proliferation	   of	   peroxisomes	   and	   hepatic	   hyperplasia	   when	   administered	   to	  
rodents.	  Effects	  of	  administration	  of	  this	  class	  of	  compounds	  includes	  increased	  transcription	  of	  
genes	   involved	   in	   peroxisomal	   FA	   β-­‐oxidation	   (catabolism	   of	   long	   chain	   FAs)	   and	   increased	  
transcription	  of	  the	  cytochrome	  P450	  IV	  family	  genes	  (Issemann	  and	  Green,	  1990).	  
	  
Activation	  of	  Pparα:	  
	   The	   actions	   of	   Pparα	   activation	   occur	   through	   the	   modulation	   of	   Pparα-­‐responsive	  
genes.	   These	   hundreds	   of	   genes,	   which	   contain	   a	   PPRE	   in	   their	   promoter,	   encode	   proteins	  
involved	   in	   functions	   such	   as	   microsomal,	   peroxisomal	   and	   mitochondrial	   FA	   oxidation,	  
gluconeogenesis,	   triglyceride	   turnover,	  bile	   synthesis,	  bile	   secretion,	   and	   retinoid	  metabolism	  
(Kersten,	   2014).	   The	   genes	   targeted	   by	   Pparα	   activation	   are	   numerous	   and	   encode	   proteins	  
such	  as	  Vanin	  1	   (Vnn1),	  Acyl-­‐CoA	  oxidase	  1	   (Acox1),	  pyruvate	  dehydrogenase	  kinase	  4	   (Pdk4)	  
and	  Cyp4a10.	  
	  
Vanin	  1:	  Vnn1	  is	  an	  enzyme,	  specifically	  a	  pantetheinase,	  which	  is	  anchored	  to	  the	  cell	  
surface	  by	  a	  glycosylphosphatidylinositol	  (GPI)	  moiety.	  Vnn1	  is	  mostly	  expressed	  in	  the	  
liver,	  kidney	  and	  gastrointestinal	  tract	  and	  it	  functions	  in	  the	  hydrolysis	  of	  pantetheine	  
to	   vitamin	   B5	   (pantotheic	   acid)	   and	   cysteamine	   (Chen	   et	   al.,	   2014).	   Vitamin	   B5	   is	   a	  
required	  component	  of	  Coenzyme	  A	  (CoA)	  synthesis.	  CoA	  is	  a	  coenzyme	  that	  plays	  a	  role	  
in	  the	  synthesis	  and	  degradation	  of	  FA	  by	  transporting	  intermediates	  between	  enzyme	  
active	   sites	   (Leonardi	   and	   Jackowski,	   2007).	   Cysteamine	   is	   an	   aminothiol,	   which	   has	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been	  shown	  to	  possess	  some	  antioxidant	  activity.	  Cysteamine	  appears	  to	  decrease	  ROS	  
mainly	   through	   conversion	   to	   the	   amino	   acid	   taurine	   and	   increasing	   levels	   of	   the	  
antioxidant	   enzyme	   superoxide	   dismutase.	   Cysteamine	   also	   has	   functions	   as	   an	   iron	  
chelator,	  which	  reduces	  the	  production	  of	  reactive	  hydroxyl	  radicals	   in	  the	  cell	   (Petrov	  
et	  al.,	  2012).	  
	  
Acyl-­‐CoA	   oxidase	   1:	   Acox1	   was	   the	   first	   Pparα-­‐responsive	   gene	   to	   be	   identified	   and	  
encodes	   the	  enzyme	   involved	   in	   the	   first	   (and	   rate-­‐limiting)	   step	  of	  peroxisomal	   long-­‐
chain	  FA	  oxidation	  (Kersten,	  2014).	  	  
	  
Pyruvate	  dehydrogenase	  kinase	  4:	  Pdk4	   is	  an	  enzyme	  that	   is	  normally	  activated	  during	  
periods	   of	   fasting.	   It	   inactivates	   pyruvate	   dehydrogenase	   (PDH)	   through	  
phosphorylation.	  Inactivation	  of	  PDH	  results	  in	  a	  switch	  in	  fuel	  sources	  from	  oxidation	  of	  
carbohydrates	  to	  oxidation	  of	  fat	  (Wang	  and	  Sahlin,	  2012).	  	  
	  
Cyp4a10:	  Cyp4a10	   is	  a	  member	  of	   the	  Cyp4a	   subfamily	  of	  phase	   I	  metabolic	  enzymes	  
known	   as	   cytochrome	   P450s.	   The	   Cyp4a	   subfamily	   is	   expressed	   in	   the	   rough	  
endoplasmic	  reticulum	  of	  hepatocytes	  and	  functions	  in	  the	  ω	  hydroxylation	  of	  medium	  
and	   long	   chain	   FAs.	   They	   oxidize	   the	   terminal	   C-­‐H	   bond	   of	   FAs,	   which	   initiates	   the	  
degradation	  and	   conversion	  of	   the	  FA	   to	  dicarboxylic	   acids.	   The	  dicarboxylic	   acids	   are	  
then	  converted	  to	  fuels	  by	  β-­‐oxidation	  in	  the	  mitochondria	  or	  peroxisome	  (Nyagode	  et	  
al.,	  2014).	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Species	  Differences:	  
	   Peroxisome	   proliferators	   are	   classified	   as	   non-­‐genotoxic	   hepatocarcinogens,	   meaning	  
that	   they	  have	  been	  demonstrated	   to	  produce	   liver	   tumors	  when	  chronically	  administered	   in	  
rodents	   (Gonzalez	   and	   Shah,	   2008).	   The	   peroxisome	   proliferators	   are	   classified	   as	   non-­‐
genotoxic	   because	   they	   cause	   tumor	   formation	   without	   direct	   interaction	   with	   DNA.	   Non-­‐
genotoxic	   carcinogens	   typically	   act	   by	   increasing	   cellular	   proliferation,	   disrupting	   cellular	  
structures	  or	  creating	  an	  environment	  that	  increases	  the	  risk	  of	  mutations	  being	  formed	  (Lee	  et	  
al.,	  2013).	  In	  rodents,	  the	  administration	  of	  peroxisome	  proliferators	  causes	  increased	  liver	  size	  
(hepatomegaly),	   hepatocyte	   proliferation,	   peroxisome	   proliferation	   and	   oxidative	   stress.	   The	  
oxidative	   stress	   is	   mostly	   due	   to	   the	   increased	   production	   of	   the	   acyl-­‐CoA	   oxidase	   (Aox)	  
enzyme.	   During	   the	   AOX-­‐catalyzed	   step	   in	   fatty	   acid	   oxidation,	   hydrogen	   peroxide	   (H2O2)	   is	  
produced	  as	  a	  byproduct	  (Gonzalez	  and	  Shah,	  2008).	  Increased	  levels	  of	  H2O2	  yields	  increased	  
oxidative	   stress,	   which	   could	   lead	   to	   the	   formation	   of	   DNA	   adducts	   and	   subsequent	   gene	  
mutations.	   Also,	   due	   to	   the	   ability	   of	   H2O2	   to	   diffuse	   out	   of	   peroxisomes,	   damage	   to	   other	  
cellular	  structures	  can	  occur.	  H2O2	  has	  also	  been	  shown	  to	   interfere	  with	  the	  cell	  survival	  and	  
apoptosis	  pathways	   through	  activation	  of	  NF-­‐κB,	  protein	   kinase	  C	   (a	   cell	   cycle	   regulator)	   and	  
activator	   protein	   1	   (Ap-­‐1;	   a	   cell	   growth	   and	   apoptosis	   regulator)	   (Reuter	   et	   al.,	   2010).	   The	  
increased	   oxidative	   stress,	   damage	   to	   cellular	   structures,	   increased	   cell	   survivability	   and	  
decreased	  apoptosis	  serve	  as	  possible	  mechanisms	  for	  hepatocarcinogenesis	  in	  rodents	  treated	  
chronically	  with	  peroxisome	  proliferators.	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   Peroxisome	  proliferation	  and	  liver	  tumor	  formation,	  however,	  have	  only	  been	  observed	  
in	  rodents.	  A	  one	  year	  feed	  study	  in	  rats	  and	  mice	  with	  the	  peroxisome	  proliferator	  WY-­‐14,643	  
resulted	   in	   a	   100%	   incidence	   of	   liver	   tumors,	  whereas	   no	   incidences	   have	   been	   observed	   in	  
epidemiological	   studies	   for	  human	  patients	   receiving	  similar	  doses	  of	   fibrate	  drug	   treatments	  
(Gonzalez	  et	  al.,	  1998).	  The	  species	  difference	  could	  be	  partially	  due	  to	  the	  tenfold	  decrease	  in	  
Pparα	   messenger	   RNA	   (mRNA)	   expression	   in	   humans	   compared	   to	   mice.	   This	   difference	  
suggests	   that	  mice	  are	  much	  more	  susceptible	   to	  activation	  of	  Pparα	  signaling	   (Palmer	  et	  al.,	  
1998).	  Another	  difference	  lies	  in	  the	  lack	  of	  a	  functional	  PPRE	  in	  the	  promoter	  of	  human	  AOX.	  In	  
rodents,	   peroxisome	   proliferators	   increase	   the	   transcription	   of	   the	   Aox	   gene	   in	   a	   Pparα-­‐
dependent	   manner,	   however	   the	   human	   AOX	   gene	   is	   not	   responsive	   to	   peroxisome	  
proliferators	  (Lambe	  et	  al.,	  1999).	  	  
	   Despite	  the	  apparent	  decrease	  in	  Pparα	  function	  and	  the	  resistance	  to	  the	  proliferative	  
effects	   of	   Pparα	   activation,	   the	   hypolidpidermic	   effects	   of	   peroxisome	   proliferators	   are	   still	  
present	   in	  humans	  and	  other	  non-­‐rodent	  mammals	   (Yang	  et	   al.,	   2008).	   Studies	  performed	   in	  
Pparα-­‐humanized	  mice	  determined	  that	  there	  are	  differences	  in	  the	  regulation	  of	  the	  cell-­‐cycle	  
control	  gene	  cMyc	  in	  wild	  type	  and	  the	  humanized	  mice.	  In	  wild	  type	  mice	  let-­‐7c,	  a	  microRNA	  
regulating	  c-­‐myc	  RNA,	  is	  suppressed	  by	  Pparα	  activation,	  resulting	  in	  increased	  levels	  of	  c-­‐myc	  
RNA	  and	  increased	  proliferation.	  In	  the	  Pparα-­‐humanized	  mice,	  however,	  Pparα	  activation	  did	  
not	  lead	  to	  suppression	  of	  let-­‐7c.	  As	  a	  result,	  there	  is	  no	  increase	  in	  c-­‐myc	  RNA	  and	  proliferation	  
is	  not	  altered	  (Gonzalez	  and	  Shah,	  2008).	  	   	  
	  
1.3.2	  Pparβ/δ:	  
	   13	  
Pparβ/δ	  was	  cloned	  in	  both	  humans	  and	  Xenopus	  in	  1992	  (Dreyer	  et	  al.,	  1992;	  Schmidt	  
et	   al.,	   1992).	   Pparβ/δ	   is	   ubiquitously	   expressed,	   but	   is	   expressed	   at	   the	   highest	   levels	   in	   the	  
brain,	  adipose	  tissue	  and	  skin.	  The	  functions	  and	  targets	  of	  Pparβ/δ	  are	  not	  very	  well	  known,	  
however	   it	   is	   known	   to	   have	   some	   function	   in	   FA	   metabolism	   and	   in	   the	   inhibition	   of	  
macrophage	  derived	  inflammation	  (Tyagi	  et	  al.,	  2011).	  	  
	  
1.3.3	  Pparγ:	  
	   Pparγ	  was	  first	  cloned	  in	  Xenopus	  in	  1992,	  which	  was	  followed	  by	  its	  cloning	  in	  humans	  
in	  1995	  (Greene	  et	  al.,	  1995;	  Schmidt	  et	  al.,	  1992).	  Pparγ	  has	  two	  protein	  isoforms	  in	  humans	  
that	   are	   differentially	   expressed	   throughout	   the	  body.	   γ1	   is	   ubiquitously	   expressed	   and	   γ2	   is	  
found	  in	  adipose	  tissue	  (Zieleniak	  et	  al.,	  2008).	  	  
Pparγ	   is	   activated	  by	  a	  wide	   variety	  of	   ligands,	   including	   FA	  derivatives,	  prostaglandin	  
derivatives	  and	  thiazolidinediones	  (TZDs).	  TZDs	  are	  a	  drug	  class	  with	  have	  high	  affinity	  for	  Pparγ	  
and	  act	  to	  increase	  insulin	  responsiveness	  in	  type	  II	  diabetes	  mellitus	  patients	  (Zieleniak	  et	  al.,	  
2008).	   Pparγ	   activation,	   through	   ligand	   binding,	   is	   followed	   by	   association	   with	   the	   PPRE	   of	  
target	  genes,	  which	  leads	  to	  the	  modulation	  of	  their	  transcription.	  These	  target	  genes	  encode	  
proteins	   involved	   in	   the	   regulation	   of	   FA	   storage,	   glucose	   metabolism	   and	   adipocyte	  
differentiation	   (Tyagi	   et	   al.,	   2011).	   Activation	   of	   Pparγ	   has	   also	   been	   associated	   with	   anti-­‐
inflammatory	  effects,	  due	  to	  inhibition	  of	  inflammatory	  cytokines	  (Delerive,	  2001).	  
	   	  
Activation	  of	  Pparγ:	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   Pparγ,	   just	   like	   Pparα,	   enacts	   its	   effects	   through	   the	   regulation	   of	   target	   gene	  
transcription.	   These	   PPRE-­‐containing	   genes	   encode	   proteins	   involved	   in	   adipocyte	  
differentiation,	   lipid	   and	   glucose	   storage	   and	   in	   decreasing	   inflammation.	   Pparγ	   targets	  
numerous	  genes,	  such	  as	  solute	  carrier	  family	  27	  member	  1	  (Slc27a1;	  fatty	  acid	  transporter	  1	  
(Fatp1)),	   lipoprotein	   lipase	   (Lpl),	   glucose	   transporter	   type	   4	   (Glut4;	   solute	   carrier	   family	   2	  
member	  4	  (Slc2a4)),	  and	  fatty	  acid	  binding	  protein	  4	  (Fabp4).	  
	  
Slc27a1:	  Slc27a1,	  or	  Fatp1,	  is	  a	  member	  of	  the	  fatty	  acid	  transport	  protein	  (Fatp)	  family	  
of	   transporters	   involved	   in	   the	  uptake	  of	   long	   chain	  FAs.	   It	   is	  mainly	  expressed	   in	   the	  
heart,	   adipose	   and	   skeletal	  muscle,	   but	   also	   has	   low	   levels	   of	   expression	   in	   the	   liver,	  
kidney,	  brain	  and	  lung	  (Guitart	  et	  al.,	  2014).	  	  
	  
Lipoprotein	   lipase:	   Lpl	   is	   the	   enzyme	   that	   catalyzes	   the	   rate-­‐limiting	   step	   of	  
triacylglycerol	   (TAG)	   hydrolysis.	   Lpl	   acts	   to	  metabolize	   TAGs,	   located	   in	   chylomicrons,	  
and	  very	  low-­‐density	  lipoproteins	  (VLDL)	  into	  free	  FAs,	  which	  can	  then	  be	  stored	  as	  TAGs	  
in	  adipocytes	  or	  be	  oxidized	  and	  used	  for	  energy.	  It	  is	  widely	  distributed	  throughout	  the	  
body,	   including	   in	   adipose	   tissue,	   liver,	   kidney,	   heart	   and	   skeletal	  muscle.	   Due	   to	   the	  
role	  of	  Lpl	  in	  lipid	  metabolism	  it	  is	  important	  to	  note	  that	  the	  enzymatic	  activity	  of	  Lpl	  is	  
tissue-­‐specific	   and	   depends	   on	   whether	   the	   system	   is	   in	   a	   fed	   or	   fasted	   state.	   For	  
example,	   during	   a	  period	  of	   fasting,	   Lpl	   expression	   is	   decreased	   in	   adipose	   tissue	  and	  
increased	   in	   the	   heart,	   resulting	   in	   free	   FAs	   being	   used	   for	   energy	   instead	   of	   being	  
stored	  (Braun	  and	  Severson,	  1992).	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Glucose	  transporter	  type	  4:	  Glut4	  is	  a	  member	  of	  a	  family	  of	  sugar	  transporters,	  which	  
either	   import	   or	   export	   sugar	   molecules	   through	   facilitated	   diffusion.	   Glut4	   is	   the	  
isoform	   involved	   in	   the	   uptake	   of	   glucose	   from	   systemic	   circulation	   and	   thus	   plays	   a	  
large	   role	   in	  maintaining	  glucose	  homeostasis.	   It	   is	  expressed	  at	  high	   levels	   in	   skeletal	  
muscle	  and	  adipose	  tissue,	  but	  can	  also	  be	  found	  at	  low	  levels	  in	  other	  tissues,	  such	  as	  
the	  liver.	  Alterations	  to	  the	  expression	  of	  Glut4	  transporters	  have	  serious	  consequences.	  
For	   example,	   depletion	   of	   Glut4	   leads	   to	   insulin	   resistance	   and	   the	   development	   of	  
diabetes	  (Huang	  and	  Czech,	  2007).	  
	  
Fatty	  acid	  binding	  protein	  4:	  Fabp4	  is	  a	  member	  of	  the	  fatty	  acid	  binding	  protein	  family	  
of	  cytoplasmic	  proteins.	  Fabp4	  is	  mainly	  expressed	  in	  adipose	  tissue	  and	  macrophages,	  
but	   also	   has	   some	   expression	   in	   the	   liver.	   It	   acts	   as	   a	   chaperone	   for	   FAs	   in	   various	  
signaling	   pathways	   by	   transporting	   intracellular	   lipids	   to	   biological	   targets	   (Garin-­‐
Shkolnik	  et	  al.,	  2014).	  
	  
1.4	  Rxr:	  
	   The	  retinoid	  X	  receptors	  (Rxrs)	  are	  a	  family	  of	  nuclear	  receptors	  that	  bind	  retinoic	  acid	  
metabolites,	  such	  as	  9-­‐cis	  retinoic	  acid,	  and	  have	  the	  ability	  to	  form	  stable	  heterodimers	  with	  
many	   receptors,	   including	   retinoic	  acid	   receptors	   (Rars),	  Ppars,	  vitamin	  D	   receptors	   (Vdr)	  and	  
thyroid	  hormone	  receptors	  (Tr)	  (Mangelsdorf	  et	  al.,	  1992).	  The	  various	  Rxr	  heterodimers	  act	  in	  
the	  transcriptional	  regulation	  of	  energy	  balance,	  through	  appetite	  and	  fuel	  usage.	  Heterodimers	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formed	   with	   Rxr	   can	   either	   be	   permissive	   or	   non-­‐permissive.	   The	   Rxr-­‐Ppar	   heterodimer	   is	  
permissive	  because	  only	  binding	  of	  a	  Ppar-­‐selective	  ligand	  is	  required	  to	  activate	  the	  complex.	  
Rxr-­‐Rar,	  Rxr-­‐Vdr	  and	  Rxr-­‐Tr	  heterodimers	  are	  non-­‐permissive,	  meaning	  activation	  can	  only	  be	  
achieved	  through	  separate	  binding	  of	  an	  Rxr-­‐selective	  and	  a	  partner-­‐selective	  ligand.	  
There	   are	   three	  differentially	   expressed	   subtypes	  of	   Rxr,	  mainly	   Rxrα,	   Rxrβ,	   and	  Rxrγ.	  
Rxrα	  is	  mainly	  expressed	  in	  the	  liver,	  kidney,	  intestine	  and	  muscle.	  Rxrβ	  is	  expressed	  throughout	  
the	  body.	  Rxrγ	  is	  expressed	  in	  the	  brain,	  cardiac	  muscle,	  and	  skeletal	  muscle	  (Pérez	  et	  al.,	  2012).	  
Studies	   in	   knockout	  mice	  have	  demonstrated	   that	   loss	  of	  Rxrα	  produces	  more	   severe	  effects	  
than	   knockout	   of	   either	   Rxrβ	   or	   Rxrγ.	   In	   fact,	   absence	   of	   Rxrβ,	   Rxrγ,	   or	   both	   can	   be	  
compensated	  for	  in	  most	  tissues	  by	  the	  action	  of	  Rxrα	  (Ahuja	  et	  al.,	  2003).	  
There	   is	   not	   much	   evidence	   suggesting	   the	   three	   Rxr	   subtypes	   have	   different	  
heterodimer	  partners	  or	   functions,	  however,	   it	  has	  been	  demonstrated	   that	  Rxrα	   is	   the	  most	  
prominent	   form	   involved	   in	   development.	   Rxrα	   knockout	   in	  mice	   is	   embryonic	   lethal	   due	   to	  
cardiac	  ventricle	  hypoplasia	  and	  errors	  in	  the	  division	  of	  the	  ventricles.	  The	  lethal	  effects	  arise	  
from	   the	   inability	   of	   Rxr-­‐Rar	   heterodimer	   formation,	   which	   prevents	   the	   activation	   of	  
downstream	   Rar-­‐targets.	   In	   a	   Ppar-­‐dependent	   manner,	   Rxrα	   is	   also	   involved	   in	   the	  
differentiation	  of	   adipocytes,	   the	   regulation	  of	   lipolysis	   and	   in	   regulating	  hepatocyte	   lifespan	  
and	   regeneration	   (Ahuja	   et	   al.,	   2003).	   Rxrβ	   and	   Rxrγ	   play	   roles	   in	   the	   dopamine-­‐signaling	  
pathway	  and	  double	   knockout	   in	  mice	   causes	  defects	   in	   locomotion	  as	   a	   result	   of	  decreased	  
dopamine	  signaling.	  Knockout	  of	  Rxrβ	  causes	  embryonic	  lethality	  in	  about	  50%	  of	  mutant	  mice	  
due	  to	  defects	  in	  placenta	  formation	  (Ahuja	  et	  al.,	  2003).	  Knockout	  of	  Rxrγ,	  however,	  produces	  
mice	  that	  mostly	  appear	  unaffected.	  Some	  observed	  effects	   include	   increased	  metabolic	  rate,	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reduced	  food	  consumption	  and	  increased	  activity	  of	  lipoprotein	  lipase	  in	  skeletal	  muscle	  (Pérez	  
et	  al.,	  2012).	  
	  
Activation	  of	  Rxrα:	  
	   Rxrα,	   either	   as	   a	   homodimer	   or	   heterodimer,	   acts	   to	   regulate	   the	   activity	   of	   other	  
nuclear	   receptors.	   In	   the	   absence	   of	   a	   ligand,	   Rxrα	   binds	   a	   complex	   of	   co-­‐repressors	   that	  
prevent	   its	   activity.	  Binding	  of	  a	   ligand	  displaces	   this	   complex	  of	   co-­‐repressors	  and	   recruits	  a	  
complex	  of	  co-­‐activators	  that	  allow	  for	  Rxrα	  to	  bind	  DNA	  and	  regulate	  transcription,	  depending	  
on	  the	  heterodimer	  partner.	  Permissive	  heterodimers	  are	  activated	  by	  ligand	  binding	  to	  Rxrα,	  
however,	  non-­‐permissive	  heterodimers	  require	  both	  the	  Rxrα-­‐specific	   ligand	  and	  the	  partner-­‐
specific	  ligand	  to	  be	  bound.	  In	  both	  cases,	  activation	  of	  the	  Rxrα	  heterodimer	  targets	  numerous	  
genes	  involved	  in	  many	  different	  regulatory	  pathways.	  Some	  of	  the	  proteins	  encoded	  by	  these	  
genes	  are	  the	  retinoic	  acid	  receptor	  α	   (Rarα),	  deiodinase	   I	   (Dio1),	  Cyp2r1,	  and	  retinol	  binding	  
protein	  1	  (Rbp1).	  
	  
Retinoic	  acid	   receptor	  α:	  Rarα	   is	  a	   subtype	  of	   the	  Rar	   family	  of	  nuclear	   receptors.	  Rar	  
forms	  a	  heterodimer	  with	  Rxr,	  which	  then	  binds	  to	  the	  retinoic	  acid	  response	  element	  
(RARE)	   in	   the	   promoters	   of	   target	   genes.	   The	   Rar-­‐Rxr	   heterodimer	   regulates	   the	  
transcription	   of	   genes	   involved	   in	   cell-­‐cycle	   arrest,	   cell	   differentiation	   and	   cell	   death	  
(Kalitin	  and	  Karamysheva,	  2016).	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Deiodinase	  1:	  Dio1	  is	  a	  hepatic	  enzyme	  that	  converts	  the	  pro-­‐hormone	  thyroxine	  (T4)	  to	  
the	   active	   thyroid	   hormone	   triiodothyronine	   (T3)	   (Yu	   and	   Koenig,	   2006).	   Dio1	   is	   a	  
downstream	   target	   of	   thyroid	   hormone	   receptor	   activity	   and	   is	   regulated	   by	   the	   Rxr-­‐
thyroid	  hormone	  receptor	  heterodimer.	  	  
	  
Cyp2r1:	   Cyp2r1	   is	   a	   member	   of	   the	   cytochrome	   P450	   family	   of	   phase	   I	   metabolic	  
enzymes.	   Cyp2r1	   catalyzes	   the	   second	   step	   in	   the	   synthesis	   of	   active	   vitamin	   D.	   This	  
second	   step	   occurs	   in	   the	   liver	   and	   hydroxylates	   carbon	   25	   of	   vitamin	   D	   to	   form	   25-­‐
hydroxyvitamin	  D3.	  The	  final	  step	  occurs	  via	  cytochrome	  P450	  metabolism	  in	  the	  kidney,	  
which	  produces	  the	  Vdr	  ligand	  1α,25-­‐dihydroxyvitamin	  D3	  (Cheng	  et	  al.,	  2004).	  Cyp2r1	  is	  
a	   downstream	   target	   of	   vitamin	   D	   receptor	   activity	   and	   is	   regulated	   by	   the	   Rxr-­‐Vdr	  
heterodimer.	  
	   	  
Retinol	   binding	   protein	   1:	   Rbp1	   is	   a	   Rarα	   target	   gene	   that	   functions	   as	   a	   chaperone	  
protein	   for	   retinol.	   Retinol	   bound	   to	   Rbp1	   is	   the	   preferred	   substrate	   for	   retinol	  
dehydrogenase,	  which	  converts	  retinol	  to	  all-­‐trans	  retinoic	  acid.	  All-­‐trans	  retinoic	  acid	  is	  
required	  for	  proper	  signaling	  and	  differentiation	   in	  several	  tissue	  types	  (Pierzchalski	  et	  
al.,	  2014).	  	  
	  
1.5	  Acetaminophen:	  
	   Acetaminophen	   (APAP;	   Paracetamol)	   is	   a	   commonly	   used	   analgesic	   and	   antipyretic	  
compound	   that	   is	   found	   in	  many	   over	   the	   counter	   and	   prescription	   pain	   relief	  medications.	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Administration	   of	   therapeutic	   doses	   (roughly	   four	   grams	   over	   a	   24	   hour	   period)	   does	   not	  
typically	  cause	  any	  adverse	  effects,	  however,	  the	  common	  consumption	  of	  much	  larger	  doses	  
has	  made	  APAP	  one	  of	  the	  leading	  causes	  of	  drug	  induced	  liver	  injury	  (DILI).	  APAP	  overdose	  in	  
the	  United	  States	  alone	  is	  responsible	  for	  approximately	  30,000	  hospitilizations	  and	  300	  deaths	  
annually	  (Yoon	  et	  al.,	  2016).	  	  
	  
Mechanism	  of	  Hepatotoxicity:	  
	   Acetaminophen	  is	  a	  weak	  acid	  that	  is	  rapidly	  absorbed	  into	  the	  systemic	  circulation	  from	  
the	   duodenum	   after	   oral	   administration,	   but	   the	   rate	   of	   absorption	   can	   be	   delayed	   by	   the	  
concurrent	   consumption	   of	   food.	   The	   metabolism	   of	   APAP	   occurs	   mostly	   by	   microsomal	  
enzymes,	  with	  only	  about	  two	  percent	  of	  APAP	  being	  excreted	  in	  the	  urine	  unchanged.	  	  
At	   therapeutic	   levels,	   APAP	   phase	   II	   conjugation	   enzymes,	   mainly	   UDP-­‐glucuronosyl	  
transferase	  (Ugt)	  and	  sulfotransferase	  (Sult),	  metabolize	  about	  90	  percent	  of	  APAP.	  Ugt	  and	  Sult	  
catalyze	   the	   addition	   of	   polar	   groups	   to	   APAP,	   resulting	   in	   the	   formation	   of	   polar	  
glucuronidated	   and	   sulfated	   metabolites	   that	   are	   more	   easily	   excreted	   in	   the	   urine.	   The	  
remaining	  APAP	  enters	  a	  phase	  I	  oxidative	  pathway	  catalyzed	  mainly	  by	  the	  cytochrome	  P450	  
enzyme	   Cyp2e1,	   with	   contributions	   also	   by	   Cyp1a2	   and	   Cyp3a4.	   The	   APAP	   entering	   this	  
pathway	   is	  metabolized	   into	   the	   highly	   reactive	   N-­‐acetyl-­‐para-­‐benzo-­‐quinone	   imine	   (NAPQI).	  
Normally,	  NAPQI	   is	   scavenged	   and	   detoxified	   by	   intracellular	  GSH	   stores.	   The	  metabolites	   of	  
APAP	  are	  then	  exported	  from	  the	  hepatocytes	  by	  phase	  III	  transporters,	  either	  into	  the	  bile	  or	  
into	  blood	  for	  subsequent	  urinary	  excretion	  (Yoon	  et	  al.,	  2016).	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At	  supratherapeutic	  doses	  of	  APAP	  the	  Ugt	  and	  Sult	  pathways	  become	  saturated	  and	  a	  
greater	   portion	   of	   APAP	   is	   metabolized	   to	   NAPQI	   by	   Cyp2e1.	   The	   increased	   production	   of	  
NAPQI	  depletes	  GSH	  stores,	  allowing	  NAPQI	  to	  form	  protein	  adducts.	  The	  formation	  of	  protein	  
adducts	   in	   the	   mitochondria	   causes	   mitochondrial	   oxidative	   stress,	   opening	   of	   the	  
mitochondrial	   permeability	   transition	   pore	   and	   eventually	   mitochondrial	   lysis.	   This	   leads	   to	  
cellular	   DNA	   damage,	   ATP	   depletion,	   and	   eventually	   centrilobular	   hepatocellular	   necrosis	  
(McGill	  et	  al.,	  2012).	  	  	  
	  
Treatment	  of	  Acetaminophen-­‐Induced	  Hepatotoxicity:	  
	   The	  only	  available	  treatment	  for	  APAP-­‐induced	  hepatotoxicity	  is	  to	  replenish	  GSH	  stores	  
using	  a	  sulfhydryl	  donor,	  such	  as	  N-­‐Acetylcysteine	  (NAC).	  NAC	   is	  preferred	  to	  other	  sulfhydryl	  
donors,	   such	  as	  methionine,	   cysteine	  and	  cysteamine,	  due	   to	   its	   low	   toxicity	  and	   the	  ease	  of	  
administration.	   Administration	   of	   NAC,	   either	   orally	   or	   intravenously,	   within	   12	   to	   24	   hours	  
following	  APAP	  overdose,	  serves	  as	  an	  effective	  antidote	  to	  APAP	  hepatotoxicity.	  NAC	  acts	  to	  
increase	  the	  synthesis	  of	  GSH,	  providing	  the	  hepatocytes	  with	  an	  increased	  ability	  to	  scavenge	  
and	   detoxify	   NAPQI	   and	   also	   to	   counteract	   the	   oxidative	   stress	   produced	   by	   this	   reactive	  
metabolite	   (Lauterburg	   et	   al.,	   1983).	  NAC	   serves	   as	   an	   effective	   treatment	   for	   APAP-­‐induced	  
hepatotoxicity,	   as	   long	   as	   symptoms	   can	   be	   identified	   early.	   The	   lack	   of	   other	   treatments	  
highlights	   the	  need	   for	  a	  better	  understanding	  of	   the	  mechanism	  of	  APAP	  hepatotoxicity	  and	  
the	  identification	  of	  other	  factors	  that	  can	  be	  useful	  in	  treatment	  or	  prevention.	  
	  
1.5.1	  Role	  of	  Nrf2	  in	  Protection	  from	  Acetaminophen-­‐Induced	  Hepatotoxicity:	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   In	   the	   presence	   of	   oxidative	   stress	   Nrf2	   is	   able	   to	   translocate	   and	   accumulate	   in	   the	  
nucleus,	   where	   it	   upregulates	   the	   transcription	   of	   a	   series	   of	   antioxidant	   response	   genes.	  
Studies	   have	   shown	   that	   there	   is	   a	   linear	   relationship	   between	   increasing	   APAP	   dose	   (from	  
nontoxic	   to	   toxic	   doses)	   and	   increased	   nuclear	   accumulation	   of	   Nrf2	   in	   mouse	   liver.	   The	  
increased	  nuclear	  accumulation	  is	  also	  accompanied	  by	  an	  increase	  in	  Nrf2	  activity,	  as	  shown	  by	  
elevated	  mRNA	   expression	   of	   the	   Nrf2-­‐dependent	   genes	   Nqo1,	   Hmox1	   and	   Gclc	   (Aleksunes,	  
2006;	  Goldring	  et	  al.,	  2004).	  This	   is	   supported	  by	  studies	  analyzing	   the	  effects	  of	  hepatocyte-­‐
specific	  knockouts	  of	  Keap1	  in	  mice.	  These	  mice	  have	  elevated	  levels	  of	  Nrf2	  in	  the	  liver,	  as	  well	  
as	   increased	  accumulation	  of	  Nrf2	   in	  the	  nucleus	  and	   increased	  mRNA	  expression	  of	  the	  Nrf2	  
target	  genes	  Nqo1	  and	  Gclc.	  Also,	  the	  Keap1	  mutant	  mice	  display	  very	  few	  signs	  of	  liver	  injury,	  
compared	  to	  wild	  type	  mice,	  following	  administration	  of	  normally	  toxic	  doses	  of	  APAP	  (Okawa	  
et	  al.,	  2006).	  
	   Studies	  using	  Nrf2	  knockout	  mice	  have	   illustrated	   that	   lack	  of	  Nrf2	   function	  causes	  an	  
increased	   susceptibility	   to	   APAP-­‐induced	   liver	   insults.	   The	   knockout	  mice	   had	   high	  mortality	  
rates	   at	   doses	   that	   are	   nonlethal	   in	  wild	   type	  mice.	   This	   is	   in	   part	   due	   to	   significantly	   lower	  
intracellular	  stores	  of	  GSH	  that	  accompany	  knockout	  of	  Nrf2	  (Chan	  et	  al.,	  2001).	  Nrf2	  knockout	  
mice	   also	   exhibit	   decreased	   expression	   of	  mRNA	   and	   protein	   for	   Nqo1,	   Gclc	   and	   other	   anti-­‐
oxidant	  genes,	  supporting	  the	  decreased	  ability	  to	  tolerate	  oxidative	  stress	  and	  the	  decreased	  
production	  of	  GSH	  (Aleksunes	  et	  al.,	  2008).	  
	  
1.5.2	  Role	  of	  Pparα	  in	  Protection	  from	  Acetaminophen-­‐Induced	  Hepatotoxicity:	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   Administration	   of	   peroxisome	   proliferators	   prior	   to	   APAP	   dosing	   protects	   against	   the	  
hepatotoxic	  effects	  of	  high	  APAP	  doses.	  Ten	  day	  repeated	  dosing	  of	  mice	  using	  the	  peroxisome	  
proliferator	  clofibrate	  (CFB)	  followed	  by	  an	  APAP	  challenge	  was	  sufficient	  to	  protect	  against	  the	  
hepatotoxic	   effects	   of	  APAP	   (Manautou	  et	   al.,	   1994;	  Nicholls-­‐Grzemski	   et	   al.,	   1992).	   The	  CFB	  
pretreated	  mice	  displayed	  larger	  livers,	   increased	  intracellular	  GSH	  stores,	  lower	  levels	  of	  GSH	  
depletion	   and	   decreased	   protein	   adduct	   formation	   in	   comparison	   to	   APAP-­‐treated	  mice	   not	  
receiving	   CFB	   pretreatment	   (Manautou	   et	   al.,	   1994).	   In	   the	   development	   of	   APAP-­‐induced	  
hepatotoxicity,	  NAPQI	   covalently	   binds	   to	   selective	   cellular	   proteins	   to	   form	  adducts.	  One	  of	  
these	  targets	  is	  the	  cytosolic	  58kD	  APAP-­‐binding	  protein	  (58-­‐ABP)	  (Hoivik	  et	  al.,	  1996).	  The	  ten-­‐
day	   pretreatment	   with	   CFB	   did	   not	   change	   the	   amount	   of	   cytosolic	   58-­‐ABP,	   however	   it	   did	  
decrease	   the	   covalent	   binding	   of	   NAPQI	   to	   58-­‐ABP.	   Repeated	   dosing	   of	   peroxisome	  
proliferators	   appears	   to	   confer	   protection	   against	   APAP	   hepatotoxicity,	   possibly	   due	   to	   an	  
increase	  in	  the	  production	  of	  GSH	  (Manautou	  et	  al.,	  1994).	  	  
Unlike	   in	   the	   ten-­‐day	   dosing	  model,	   a	   single	   dose	   of	   CFB	   does	   not	   alter	   hepatic	   GSH	  
levels,	  however,	  a	  single	  dose	  of	  CFB,	  prior	  to	  APAP	  dosing,	  is	  partially	  protective	  against	  APAP	  
hepatotoxicity,	  without	  significantly	  altering	  protein	  adduct	  formation	  or	  initial	  GSH	  depletion.	  
Compared	   to	   APAP-­‐treated	   control	   mice,	   APAP-­‐treated	   mice	   receiving	   CFB	   pretreatment	  
display	   faster	   restoration	  of	  GSH	   to	   control	   levels	   (Manautou	  et	   al.,	   1996).	   This	   supports	   the	  
protective	  role	  of	  CFB	  against	  APAP	  toxicity	  because	  GSH	  restoration	  occurs	  more	  rapidly	  when	  
APAP	  dosing	  does	  not	  culminate	  in	  hepatic	  toxicity.	  Furthermore,	  a	  single	  pretreatment	  of	  CFB	  
protects	   against	   APAP	   hepatotoxicity	   without	   affecting	   hepatic	   covalent	   binding.	   Hepatic	  
covalent	  binding	  is	  a	  key	  component	  of	  APAP-­‐induced	  hepatotoxicity,	  but	  it	  is	  not	  sufficient	  by	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itself	   for	   the	   onset	   of	   toxicity.	   Oxidative	   events,	   occurring	   after	   initial	   covalent	   binding,	   are	  
believed	   to	  play	  a	   significant	   role	   in	   the	  production	  of	  cellular	  damage.	   It	   is	  possible	   that	   the	  
partial	  protection	  against	  APAP	  toxicity	  observed	  following	  a	  single	  pretreatment	  dose	  of	  CFB	  
may	   be	   mechanistically	   linked	   to	   disruption	   of	   oxidative	   events	   that	   occur	   subsequent	   to	  
covalent	  binding	  (Manautou	  et	  al.,	  1996).	  	  
	   The	  protective	  effect	  of	  CFB	  is	  dependent	  on	  the	  ability	  of	  Pparα	  to	  be	  activated.	  A	  study	  
using	  the	  ten-­‐day	  CFB	  pretreatment	  model	  in	  Pparα	  knockout	  mice	  found	  that,	  unlike	  wild	  type	  
mice,	  the	  mutant	  mice	  were	  not	  protected	  by	  CFB	  from	  the	  hepatotoxic	  effects	  of	  APAP.	  Also,	  
these	   mutant	   mice	   are	   resistant	   to	   typical	   peroxisome	   proliferator	   effects,	   such	   as	  
hepatomegaly,	   peroxisome	   proliferation	   and	   enzyme	   induction	   (Chen	   et	   al.,	   2000).	   The	  
protective	   effects	   of	   peroxisome	   proliferator	   pretreatment	   against	   APAP	   hepatotoxicity	   are	  
occurring	  in	  a	  manner	  dependent	  on	  Pparα	  activation.	  	  
	   Another	   possible	   mechanism	   for	   the	   protective	   role	   of	   Pparα	   activation	   against	  
chemically	   induced	   oxidative	   stress	   could	   be	   through	   the	   regulation	   of	   protein	   folding	   genes	  
and	  genes	  involved	  in	  proteasomal	  degradation.	  Anderson	  et	  al.	  (2004)	  performed	  a	  transcript	  
profiling	  study	  using	  wild	  type	  and	  Pparα-­‐null	  mouse	  livers	  after	  seven	  days	  of	  dosing	  with	  the	  
Pparα	  activator	  WY-­‐14,643.	  This	  study	  revealed	  that	  Pparα	  activation	  alters	   the	  expression	  of	  
genes	   encoding	   heat-­‐shock	   proteins,	   chaperone	   proteins,	   and	   proteasome	   subunits.	   The	  
possible	   role	   of	   Pparα	   activation	   in	   the	   induction	   of	   genes	   involved	   in	   the	   protein	   folding	  
pathway	  and	  genes	   involved	  in	  proteasomal	  degradation	  of	  damaged	  proteins	  may	  serve	  as	  a	  
protective	  mechanism	  against	  chemically	  induced	  oxidative	  stress	  (Anderson	  et	  al.,	  2004).	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1.6	  Signaling	  Pathway	  Interactions	  
	   The	  activation	  of	  a	  receptor	  or	  transcription	  factor	  leads	  to	  the	  transduction	  of	  a	  signal	  
along	   a	   cellular	   pathway,	   with	   the	   end	   goal	   of	   altering	   intracellular	   physiology.	   Signaling	  
pathways,	  however,	  are	  often	  complex	  and	  can	   involve	  the	   integration,	  or	  crosstalk,	  between	  
multiple	  pathways.	  	  Crosstalk	  between	  various	  transcription	  factors	  highlights	  the	  existence	  of	  
regulatory	   and	   compensatory	   mechanisms	   needed	   to	   maintain	   proper	   cellular	   function.	  
Additionally,	   different	   transcription	   factors	   can	   regulate	   genes	  with	   similar	   functions	   or	   even	  
the	  same	  genes.	  This	  redundancy	  exists	  to	  ensure	  proper	  cellular	  function	  in	  case	  one	  signaling	  
pathway	  becomes	  inhibited	  or	  is	  otherwise	  malfunctioning.	  	  
	  
1.6.1	  Nrf2	  Signaling	  Interactions	  
Evidence	   suggests	   that	   Nrf2,	   the	   transcription	   factor	   involved	   in	   cellular	   response	   to	  
oxidative	  stress,	  has	  interactions	  with	  other	  signaling	  pathways,	  including	  Notch	  and	  NF-­‐κB.	  
	   The	   Notch	   receptors	   are	   important	   in	   early	   cell	   signaling,	   cellular	   differentiation,	  
organogenesis	   and	   organ	   repair.	   Notch1	   appears	   to	   be	   the	   receptor	   subtype	   with	   the	  most	  
activity	   in	   the	   liver	   (Wakabayashi	   et	   al.,	   2015).	   Ligand	   binding	   to	   Notch1	   is	   followed	   by	   two	  
proteolytic	  cleavage	  events	  that	  allow	  the	  Notch	  intracellular	  domain	  (NICD)	  to	  translocate	  into	  
the	   nucleus.	   	   The	   NICD	   associates	   with	   the	   transcription	   factor	   recombining	   binding	   protein	  
suppressor	   of	   hairless	   (Rbpjκ)	   and	   binds	   DNA,	   leading	   to	   transcription	   of	   target	   genes.	   A	  
recognition	  sequence	  for	  the	  Notch1	  modulator	  protein	  Rbpjκ	  has	  been	  identified	  in	  the	  human	  
Nrf2	  promoter	  (Wakabayashi	  et	  al.,	  2015).	  Also,	  a	  functional	  ARE	  was	  identified	  in	  the	  promoter	  
region	  of	  the	  Notch1	  gene,	  suggesting	  the	  two	  pathways	  interact.	  Partial	  hepatectomy	  studies	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in	  Nrf2-­‐null	  mice	  demonstrated	  that	  the	  loss	  of	  Nrf2	  function	  causes	  a	  significant	  reduction	  in	  
liver	   regeneration,	   compared	   to	   wild	   type	   mice.	   NICD	   rescue	   allowed	   for	   normal	   liver	  
regeneration	  in	  Nrf2-­‐null	  mice,	  suggesting	  that	  the	  decreased	  regenerative	  capacity	  of	  Nrf2-­‐null	  
mouse	  livers	  is	  due	  to	  an	  interplay	  between	  Nrf2	  and	  Notch1	  (Wakabayashi	  et	  al.,	  2010).	  
	   The	  NF-­‐κB	   family	   of	   transcription	   factors	   are	   activated	   by	   pro-­‐inflammatory	   cytokines	  
and	  are	  involved	  in	  the	  immune	  response	  against	  bacterial	  and	  viral	  pathogens,	  inflammation,	  
cell	  proliferation	  and	  protection	  against	  ultraviolet	  radiation	  (Wardyn	  et	  al.,	  2015).	  Studies	  done	  
in	  primary	  mouse	  astrocytes,	   isolated	  from	  both	  wild	  type	  and	  Nrf2-­‐null	  mice,	  analyzed	  NF-­‐κB	  
activity	   following	   “scratch”	   injury.	   Scratching	  a	  monolayer	  of	  wild	   type	  astrocytes	  with	  a	  26G	  
needle	  causes	   increased	  DNA	  binding	  by	  NF-­‐κB	  and	   increased	  expression	  of	  pro-­‐inflammatory	  
cytokines.	  Applying	  a	  scratch	  to	  an	  astrocyte	  monolayer	  isolated	  from	  Nrf2-­‐null	  mice	  produced	  
higher	  NF-­‐κB	  activity	  compared	  to	  wild	  type	  (Pan	  et	  al.,	  2012).	  This	  study	  suggests	  that	  Nrf2	  has	  
a	   regulatory	   role	   in	   NF-­‐κB	   signaling.	   Studies	   in	   the	   human	   liver	   cancer	   cell	   line	   HepG2	   and	  
human	   embryonic	   kidney	   cell	   line	  HEK293	   determined	   that	  NF-­‐κB	   activity	   acts	   to	   antagonize	  
Nrf2	  signaling.	  This	  inhibition	  occurs	  through	  interactions	  between	  the	  NF-­‐κB	  subunit	  P65	  and	  
Keap1,	   the	  Nrf2	   regulator.	  The	  P65-­‐Keap1	   interaction	   results	   in	   translocation	  of	  Keap1	   to	   the	  
nucleus,	  where	  it	  sequesters	  Nrf2	  and	  prevents	  Nrf2	  binding	  to	  the	  ARE	  of	  target	  genes	  (Yu	  et	  
al.,	   2011).	   These	   studies	   depict	   a	   regulatory	   interplay	   between	   the	  Nrf2	   and	  NF-­‐κB	   signaling	  
pathways,	   suggesting	   a	   connection	   between	   the	   cellular	   response	   to	   oxidative	   stress	   and	  
inflammation.	  
	   	  
1.6.2	  Ppar	  Signaling	  Interactions	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  The	  Ppars	  are	  a	  family	  of	  transcription	  factors	  that	  act	  to	  regulate	  FA	  metabolism.	  Pparγ	  
activation	  plays	  an	  important	  role	  in	  adipogenesis,	  and	  activation	  of	  all	  three	  Ppar	  subtypes	  has	  
been	  linked	  to	  anti-­‐inflammatory	  effects,	  suggesting	  a	  potential	  interaction	  with	  Notch	  and	  NF-­‐
κB	  respectively.	  
	   Activation	   of	   Pparγ,	   by	   either	   endogenous	   ligands	   or	   TZDs,	   is	   all	   that	   is	   needed	   for	  
adipogenesis.	   Deficiencies	   in	   the	   Notch1	   signaling	   pathway,	   however,	   prevents	   adipocyte	  
differentiation	   in	  3T3-­‐L1	  mouse	  embryonic	   fibroblasts.	  The	  effect	  appears	   to	  be	  due	  to	  Pparγ	  
downregulation	  following	  Notch1	  abrogation	  (Garces	  et	  al.,	  1997).	  In	  another	  study,	  treatment	  
of	  mouse	  adipose-­‐derived	  mesenchymal	  stem	  cells	  with	  the	  Notch1	  ligand	  Jagged1	  resulted	  in	  
increased	  adipocyte	  formation.	  It	  is	  believed	  that	  this	  effect	  is	  due	  to	  Pparγ	  induction	  that	  was	  
observed	  following	  Notch1	  signaling	  activation	  (Ba	  et	  al.,	  2012).	  These	  studies	  provide	  evidence	  
for	   a	   possible	   interaction	   between	   the	   Notch	   and	   Pparγ	   signaling	   pathways	   in	   at	   least	   the	  
process	  of	  adipogenesis.	  	  
	   Activation	   of	   Ppars,	   such	   as	   fibrate	   activation	   of	   Pparα	   and	   TZD	   activation	   of	   Pparγ,	  
demonstrates	   anti-­‐inflammatory	   actions.	   This	   effect	   appears	   to	   occur	   through	   antagonism	  of	  
inflammatory	   pathways,	   such	   as	   NF-­‐κB	   and	   AP-­‐1,	   and	   inhibition	   of	   inflammatory	   cytokine	  
production.	  Studies	  performed	  in	  human	  aortic	  smooth	  muscle	  cells	  used	  interleukin	  1β	  (IL-­‐1β)	  
to	  induce	  mRNA	  expression	  of	  IL-­‐6,	  a	  cytokine	  and	  known	  marker	  of	  vascular	  inflammation.	  The	  
increased	  expression	  of	   IL-­‐6	  was	  reduced	   in	  cells	  co-­‐treated	  with	   IL-­‐1β	  and	  the	  Pparα	  agonist	  
WY-­‐14,643.	   The	   decreased	   expression	   of	   the	   IL-­‐6	   cytokine	   appears	   to	   be	   due	   to	   Pparα-­‐
mediated	   repression	   of	   IL-­‐6	   promoter	   activation	   through	   interactions	   with	   p65	   and	   c-­‐Jun	   (a	  
subunit	  of	  AP-­‐1).	  The	  exact	  mechanisms	  of	  these	  interactions	  are	  not	  well-­‐known,	  however	  it	  is	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known	  that	  Pparα	  can	  directly	  bind	  the	  DNA	  binding	  domain	  of	  p65	  and	  N-­‐terminal	  domain	  of	  
c-­‐Jun	   (Delerive	  et	  al.,	  1999).	  The	  authors	  also	  performed	   transfection	  assays	   in	  COS-­‐1	  cells	   (a	  
monkey	   fibroblast-­‐like	   kidney	   cell	   line)	   in	   which	   the	   activity	   of	   a	   PPRE-­‐driven	   promoter	   was	  
analyzed	  in	  the	  presence	  of	  Pparα	  and	  WY-­‐14,643.	  In	  these	  assays	  the	  reporter	  activity	  of	  the	  
PPRE-­‐containing	  gene	  was	  analyzed	  in	  the	  presence	  of	   increasing	  concentrations	  of	  the	  NF-­‐κB	  
subunit	   p65	   and	   the	   AP-­‐1	   subunit	   c-­‐Jun.	   p65	   and	   c-­‐Jun	   inhibited	   reporter	   activity	   in	   a	   dose-­‐
dependent	  manner,	  suggesting	  that	  the	  negative	  regulation	  between	  Pparα	  and	  NF-­‐κB	  or	  AP-­‐1	  
is	   bidirectional	   (Delerive	   et	   al.,	   1999).	   Altogether,	   the	   studies	   performed	   by	   Delerive	   et	   al.	  
suggest	   the	   presence	   of	   a	   connection	   between	   the	   pathways	   regulating	   cytokine	   production	  
and	  FA	  metabolism.	  	  	  
	  
1.6.3	  Interaction	  Between	  Nrf2	  and	  Rxrα	  
	   Rxrα,	  the	  heterodimer	  partner	  for	  many	  nuclear	  receptors	  including	  the	  Ppars,	  is	  crucial	  
for	  Ppar	  signaling.	  Interaction	  of	  Rxrα	  with	  other	  signaling	  molecules	  could	  have	  effects	  on	  the	  
signaling	   of	   its	   many	   heterodimer	   partners.	   Experimental	   evidence	   indicates	   that	   Rxrα	   does	  
take	  part	  in	  interactions	  with	  other	  signaling	  pathways,	  one	  of	  which	  is	  Nrf2.	  
	   A	   genome-­‐wide	   binding	   study	   (ChIP-­‐sequencing)	   for	   human	   Nrf2	   was	   performed	   in	  
cultured	   human	   lymphoblastoid	   cells,	   following	   Nrf2	   activation	   by	   the	   dietary	   antioxidant	  
sulforaphane.	  Analysis	  of	  high	  confidence	  regions	  of	  Nrf2-­‐associated	  DNA	  sequences,	  referred	  
to	   as	   Nrf2-­‐bound	   peaks,	   identified	   Rxrα	   and	   the	   Ppar	   co-­‐activator	   Pparγ	   coactivator	   1-­‐beta	  
(Pgc1β)	  as	  ARE-­‐dependent	  targets	  of	  Nrf2	  binding	  (Chorley	  et	  al.,	  2012).	  Quantitative	  real	  time	  
PCR	  (qRT-­‐PCR)	  analysis	  of	  Rxrα	  revealed	  that	  mRNA	  expression	  of	  Rxrα	  increased	  following	  Nrf2	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activation,	  either	  chemically	  using	  sulforaphane	  or	  through	  shRNA	  knockdown	  of	  Keap1	  in	  3T3-­‐
L1	  mouse	  embryonic	  fibroblast	  cells.	  Accordingly,	  mRNA	  expression	  of	  Rxrα	  decreased	  following	  
shRNA	  knockdown	  of	  Nrf2	  (Chorley	  et	  al.,	  2012).	  	  
	   	  Experimental	   evidence	   also	   indicates	   a	   role	   for	   Rxrα	   in	   the	   inhibition	   of	   Nrf2	  
transcriptional	   activity.	   Knockdown	   of	   Rxrα	   using	   siRNA	   produced	   a	   doubling	   of	   basal	  mRNA	  
expression	  for	  the	  Nrf2-­‐dependent	  genes	  aldo-­‐keto	  reductase	  1c1	  (Akr1c1)	  and	  Hmox1	  in	  Caco2	  
human	   colon	   cancer	   cells.	   Conversely,	   overexpression	   of	   Rxrα,	   by	   transfection	   of	   an	   Rxrα	  
expression	   vector	   into	   Caco2	   cells,	   led	   to	   reduced	   basal	   expression	   of	   the	   same	   genes.	   This	  
study	  denotes	   that	  Rxrα	  plays	  a	   role	   in	   the	   regulation	  of	  Nrf2-­‐dependent	  genes	   (Wang	  et	  al.,	  
2013).	  	  
In	   order	   to	   determine	   the	   extent	   of	   the	   Nrf2-­‐Rxrα	   interaction,	   a	   glutathione	   S-­‐
transferase	  (GST)	  pull-­‐down	  assay	  was	  performed	  to	  examine	  protein-­‐protein	  interactions.	  Two	  
separate	  assays	  were	  performed	   that	   revealed	   strong	   interactions	  between	  Nrf2	  and	  Rxrα.	  A	  
series	   of	   plasmids	   encoding	   GST-­‐tagged	   Nrf2	   or	   Rxrα	   were	   constructed	   and	   expressed	   in	  
Escherichia	   coli	   (E.	   coli).	   Protein	   was	   purified	   using	   GSH-­‐Sepharose	   beads	   and	   resolved	   on	   a	  
10%SDS-­‐PAGE	   gel.	   The	   first	   assay	   used	   isolated	   GST-­‐tagged	   Nrf2	   incubated	   with	   histidine-­‐
tagged	   Rxrα	   protein.	   A	   GST-­‐tagged	   control	   bound	   Rxrα	   non-­‐specifically,	   whereas	   GST-­‐tagged	  
Nrf2	  binds	  strongly	  to	  his-­‐tagged	  Rxrα.	  A	  second	  assay,	  using	  isolated	  GST-­‐tagged	  Rxrα	  protein	  
incubated	   with	   histidine-­‐tagged	   Nrf2	   protein,	   was	   performed	   to	   confirm	   the	   specificity	   of	  
binding	   between	   Nrf2	   and	   Rxrα.	   Nonspecific	   binding	   by	   the	   GST-­‐tagged	   control	   and	   strong	  
binding	   between	   Rxrα	   and	   Nrf2	   confirmed	   that	   the	   interaction	   between	   the	   two	   proteins	   is	  
specific.	   The	   authors	   also	   performed	   GST	   pull-­‐down	   assays	   using	   truncated	   GST-­‐tagged	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constructs	   of	   Nrf2	   and	   Rxrα	   protein	   to	   determine	  what	   regions	   are	   involved	   in	   binding.	   The	  
strongest	  interactions	  were	  observed	  between	  the	  Neh7	  domain	  of	  Nrf2	  and	  the	  DNA-­‐binding	  
domain	  of	  Rxrα	  (Wang	  et	  al.,	  2013).	  	  
	   ChIP	   assays	   performed	   in	  MCF7	   human	   breast	   cancer	   cells,	   following	   Nrf2	   activation	  
using	  the	  synthetic	  antioxidant	  tert-­‐butylhydroquinone,	  revealed	  that	  both	  Nrf2	  and	  Rxrα	  were	  
able	  to	  bind	  ARE	  sites	  in	  the	  promoters	  of	  Nrf2-­‐dependent	  genes.	  The	  binding	  of	  Rxrα	  to	  AREs	  
was	  much	  weaker	  than	  the	  binding	  exhibited	  by	  Nrf2	  and	  depletion	  of	  Nrf2	  reduced	  the	  ability	  
of	  Rxrα	  to	  bind	  AREs.	  The	  authors	  concluded	  that	  Rxrα	  possesses	  an	   inhibitory	  effect	  on	  Nrf2	  
signaling,	  most	  likely	  through	  the	  formation	  of	  an	  inactive	  Nrf2-­‐Rxrα	  complex	  bound	  to	  the	  ARE	  
in	  target	  genes	  (Wang	  et	  al.,	  2013).	  	  
	  
1.6.4	  Interaction	  Between	  Nrf2	  and	  Pparγ	  
Transcription	   factor	   signaling	   is	   comprised	   of	   a	   complex	   series	   of	   signaling	   and	  
regulatory	  events	  that	  often	  involve	  interactions	  with	  other	  transcription	  factors.	  The	  presence	  
of	   some	   overlapping	   actions	   between	   Nrf2	   and	   the	   Ppars	   suggest	   that	   these	   transcription	  
factors	   may	   have	   interacting	   signaling	   pathways.	   There	   is	   some	   evidence	   supporting	   the	  
existence	  of	  this	  interaction.	  
	   Protein	  analysis	  of	  Pparγ	  in	  wild	  type	  and	  Nrf2-­‐null	  mouse	  lungs	  revealed	  that	  Nrf2-­‐null	  
mice	   possess	   a	   decreased	   basal	   level	   of	   Pparγ	   protein	   expression.	   Also,	   Pparγ	   protein	  
expression	   in	  wild	   type	  mice	   increased	   significantly	   following	   48-­‐hour	   exposure	   to	   hyperoxic	  
conditions,	  whereas	   exposing	  Nrf2-­‐null	  mice	   to	   the	   same	   treatment	   produced	   no	   changes	   in	  
Pparγ	  protein	  levels.	  These	  results	  imply	  that	  Nrf2	  plays	  some	  undefined	  role	  in	  the	  regulation	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of	   Pparγ	   (Cho	  et	   al.,	   2010).	   The	  authors	  proceeded	   to	  perform	  bioinformatics	   analysis	  of	   the	  
Pparγ	   promoter	   and	   identified	   a	   potential	   ARE.	   They	   then	   cloned	   a	   region	   of	   the	   Pparγ	  
promoter	   containing	   a	  wild	   type	   version	   of	   the	   sequence	   and	   another	   containing	   a	  mutated	  
sequence	  into	  luciferase	  reporter	  vectors.	  Analysis	  of	  luciferase	  activity,	  following	  transfection	  
of	  the	  vectors	  into	  Nrf2-­‐overexpressing	  airway	  epithelial	  cells	  revealed	  that	  in	  both	  normal	  and	  
hyperoxic	  conditions,	  cells	  containing	  the	  mutated	  sequence	  had	  lower	  luciferase	  activity	  than	  
cells	   containing	   the	   wild	   type	   form.	   Through	   this	   study	   the	   authors	   determined	   that	   Nrf2	  
binding	   to	   the	   ARE	   sequence	   in	   the	   Pparγ	   promoter	   is	   required	   for	   the	   induction	   of	   Pparγ	  
expression	  following	  exposure	  to	  hyperoxia	  (Cho	  et	  al.,	  2010).	  
	   Another	   group	   of	   researchers	   studying	   adipose	   tissue	   found	   that	   the	   Nrf2-­‐mediated	  
regulation	   of	   Pparγ	   extends	   to	   adipogenesis.	   Protein	   and	   mRNA	   expression	   of	   Pparγ	   is	  
decreased	   in	   adipose	   tissue	   isolated	   from	  Nrf2-­‐null	  mice	   and	   following	   shRNA	   knockdown	  of	  
Nrf2	   in	   3T3-­‐L1	   mouse	   embryonic	   fibroblasts.	   The	   decreased	   expression	   of	   Pparγ	   leads	   to	  
impaired	  adipogenesis	  in	  the	  knockout	  mice	  and	  cell	   line.	  Conversely,	  activating	  Nrf2,	  through	  
knockdown	  of	  Keap1,	  results	  in	  increased	  adipocyte	  differentiation	  in	  3T3-­‐L1	  cells.	  This	  effect	  is	  
due	  to	  increased	  Nrf2	  binding	  in	  the	  Pparγ	  promoter	  (Pi	  et	  al.,	  2010).	  	  
	  
1.6.5	  Interaction	  Between	  Nrf2	  and	  Pparα	  
	   The	  positive	  regulation	  of	  Rxrα	  by	  Nrf2	  activation	  and	  the	  negative	  regulation	  of	  Nrf2	  by	  
Rxrα	  suggest	  the	  presence	  of	  a	  regulatory	  feedback	  loop	  between	  Nrf2	  and	  Rxrα	  signaling.	  Nrf2	  
has	  also	  been	  revealed	  to	  play	  a	  direct	  role	  in	  the	  regulation	  of	  Pparγ	  expression	  in	  models	  of	  
acute	  lung	  injury	  and	  adipogenesis.	  Nrf2	  has	  known	  interactions	  with	  the	  heterodimer	  partner	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of	  Pparα	  and	  with	  a	  member	  of	  the	  Ppar	  family	  of	  nuclear	  receptors.	  The	  extent	  to	  which	  these	  
interactions	   are	   involved	   in	   other	   tissues	   are	   not	   known,	   however	   the	   presence	   of	   these	  
interactions	   hint	   at	   a	   possible	   interaction,	   either	   direct	   or	   indirect,	   between	  Nrf2	   and	   Pparα	  
signaling.	  
	   As	  a	  subset	  to	  a	  study	  on	  the	  role	  of	  Pparα	  in	  the	  regulation	  of	  proteome	  maintenance	  
genes,	  Anderson	  et	  al.	  (2004)	  analyzed	  mRNA	  expression	  of	  stress	  modifier	  genes	  in	  the	  livers	  
of	  wild	  type	  and	  Nrf2-­‐null	  mice	  treated	  with	  the	  Pparα	  activator	  WY-­‐14,643	  for	  seven	  days.	  The	  
goal	  of	  this	  experiment	  was	  to	  determine	  whether	  or	  not	  Pparα	  was	  regulating	  stress	  modifier	  
genes	   independently	   of	   Nrf2.	   The	   authors	   also	   included	   several	   Pparα	   target	   genes	   in	   their	  
mRNA	   analysis,	   most	   likely	   to	   confirm	   that	   WY-­‐14,643-­‐mediated	   activation	   of	   Pparα	   was	  
occurring.	   The	  mRNA	  expression	   of	   Pparα	   and	   the	   Pparα-­‐dependent	   genes	   (Acox1,	   Cyp4a10,	  
Cyp4a14,	   Fabp4)	   is	   elevated	   by	   WY-­‐14,643	   treatment	   in	   wild	   type	   mice.	   The	   authors	   also	  
observed	  significantly	  higher	  mRNA	  expression	  of	  the	  Pparα	  target	  genes	  in	  WY-­‐14,643-­‐treated	  
Nrf2-­‐null	   mice,	   compared	   to	   all	   other	   treatment	   groups	   (Anderson	   et	   al.,	   2004).	   The	   up-­‐
regulation	  of	  Pparα	  target	  genes	  in	  the	  absence	  of	  Nrf2	  suggests	  a	  possible	  role	  for	  Nrf2	  in	  the	  
regulation	  of	  Pparα	  signaling.	  	  
	   Another	  group	  measured	  the	  mRNA	  expression	  of	  the	  Ppar	  gamma	  coactivator	  1-­‐alpha	  
(Pgc1α)	  in	  the	  livers	  of	  wild	  type,	  Nrf2-­‐null	  and	  Nrf2-­‐overexpressing	  mice.	  They	  were	  interested	  
in	   Nrf2-­‐mediated	   protection	   of	  mitochondria	   in	   response	   to	   oxidative	   stress	   and	   found	   that	  
Nrf2-­‐null	  mice	  had	  lower	  hepatic	  mitochondrial	  content	  compared	  to	  wild	  type.	  Their	  analysis	  
revealed	  that	  hepatic	  Pgc1α	  mRNA	  expression	  was	  elevated	  in	  Nrf2-­‐null	  mice	  after	  24	  hours	  of	  
fasting,	  compared	  to	  wild	   type	  and	  Nrf2-­‐overexpressing	  mice	   (Zhang	  et	  al.,	  2013).	  Pgc1α	  also	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serves	  as	  a	  co-­‐activator	  for	  all	  three	  members	  of	  the	  Ppar	  family.	  In	  regards	  to	  Pparα,	  periods	  of	  
fasting	   cause	   Pparα	   induction	   and	   co-­‐activation	   by	   Pgc1α,	   leading	   to	   the	   induction	   of	   genes	  
involved	   in	  hepatic	  fatty	  acid	  oxidation.	  This	  serves	  to	  switch	  fuel	  usage	  from	  glucose	  to	  fatty	  
acids	   in	   order	   to	   preserve	   glucose	   for	   use	   by	   the	   central	   nervous	   system	   (Liang	   and	  Ward,	  
2006).	  
	   Evidence	  suggests	   that	   there	   is	   some	   level	  of	   interaction	  between	  the	  Nrf2	  and	  Pparα	  
signaling	   pathways.	   Both	  Nrf2	   and	   Pparα	   are	   protective	   against	   chemically	   induced	  oxidative	  
stress	   and	   individual	   activation	   of	   either	   Nrf2	   or	   Pparα	   has	   been	   demonstrated	   to	   confer	  
tolerance	  to	  drug-­‐induced	  hepatotoxicity.	  Nrf2	  is	  already	  known	  to	  be	  involved	  in	  the	  regulation	  
of	  several	  signaling	  pathways,	  so	  a	  permissive	  role	  for	  Nrf2	   in	  the	  regulation	  of	  Pparα	  activity	  
would	   not	   be	   surprising.	   This	   proposed	   interaction,	   however,	   is	  most	   likely	   not	   direct,	   since	  
there	   is	   no	   indication	   of	   direct	   binding.	   The	   studies	   presented	   in	   this	   thesis	   have	   been	  
performed	   to	   identify	   a	  possible	  mechanism	   for	   the	   interaction	  between	  Nrf2,	   a	   regulator	  of	  
the	   antioxidant	   response	   and	   Pparα,	   a	   regulator	   of	   lipid	   homeostasis.	   It	   is	   believed	   that	   a	  
crosstalk	   between	   the	   Nrf2	   and	   Pparα	   signaling	   pathways	   contributes	   to	   changes	   in	   hepatic	  
gene	   expression	   by	   treatment	   with	   Pparα	   activators.	   The	   discovery	   of	   a	   mechanism	   for	   the	  
interaction	  between	  Nrf2	  and	  Pparα	  would	  provide	  a	  new	  insight	  into	  how	  the	  body	  responds	  
to	   chemically	   induced	   oxidative	   stress	   and	   may	   provide	   new	   targets	   for	   the	   treatment	   or	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Chapter	  2	  
	  
Role	  of	  Nrf2	  in	  the	  regulation	  of	  Ppar	  expression	  in	  mice	  
	  
2.1	  Abstract:	  
The	   peroxisome-­‐proliferator	   activated	   receptors	   (Ppars)	   are	   a	   family	   of	   ligand-­‐dependent	  
nuclear	   receptors,	   which	   promote	   transcriptional	   activation	   of	   target	   genes.	   Pparα	   regulates	  
genes	  involved	  in	  hepatic	  fatty	  acid	  transport,	  uptake	  and	  metabolism.	  Several	  of	  these	  target	  
genes	  are	  upregulated	  by	  hypolipidemic	  fibrate-­‐type	  drugs.	  Clofibrate	  (CFB)	   is	  a	  prototype	  for	  
this	   class,	   and	   a	   well-­‐known	   Pparα	   activator.	   CFB	   treatment	   also	   prevents	   liver	   injury	   by	  
acetaminophen	   (APAP)	   in	   a	   Pparα-­‐dependent	   manner.	   Similarly,	   nuclear	   factor	   erythroid	   2-­‐
related	   factor	   2	   (Nrf2)	   is	   an	   important	   genetic	   determinant	   of	   susceptibility	   to	   APAP	  
hepatotoxicity.	   The	   purpose	   of	   this	   study	   was	   to	   analyze	   the	   potential	   interaction	   between	  
Pparα	  and	  Nrf2	  signaling.	  Analysis	  of	  mRNA	  expression	  of	  Pparα-­‐related	  genes	  in	  wild	  type	  and	  
Nrf2	   knockout	   (Nrf2-­‐null)	   mice	   treated	   for	   five	   days	   with	   250mg/kg	   CFB	   suggests	   that	   Nrf2	  
regulates	  Pparα	  function.	  Gene	  expression	  of	  Pparα	  was	  not	  altered	  basally	  between	  wild	  type	  
and	   Nrf2-­‐null	   mice;	   however,	   expression	   was	   elevated	   significantly	   in	   CFB-­‐treated	   Nrf2-­‐null	  
mice,	   compared	   to	   wild	   types.	   For	   Pparα-­‐dependent	   genes	   analyzed,	   mRNA	   levels	   were	  
significantly	  increased	  with	  CFB	  treatment	  in	  both	  genotypes.	  Elevation	  was	  significantly	  higher	  
in	  CFB-­‐treated	  Nrf2-­‐null	  compared	  to	  wild	  types	  also	  receiving	  CFB.	  This	  suggests	  that	  the	  ability	  
of	   Pparα	   target	   genes	   to	   be	   induced	   is	   heightened	   in	   the	   absence	   of	   Nrf2.	   Also,	   mRNA	  
expression	  of	  Ppar	  gamma	  coactivator	  1-­‐alpha	   (Pgc1α)	  was	  elevated	   in	  Nrf2-­‐null	  mouse	   liver,	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independent	  of	  CFB	  treatment.	  Altogether,	  these	  results	  are	  indicative	  of	  a	  potential	  regulatory	  
link	  between	  Nrf2	  and	  Pparα	  signaling.	  	  
	  
2.2	  Introduction:	  	  
	   Acetaminophen	   (APAP;	   Paracetamol)	   is	   a	   commonly	   used	   analgesic	   and	   antipyretic	  
compound	   that	   is	   found	   in	  many	   over	   the	   counter	   and	   prescription	   pain	   relief	  medications.	  
APAP	  is	  safe	  when	  consumed	  at	  therapeutic	  doses.	  However,	  consumption	  of	  supra-­‐therapeutic	  
doses	  has	  made	  APAP	  one	  of	  the	  leading	  causes	  of	  drug-­‐induced	  liver	  injury	  (DILI).	  In	  the	  United	  
States	  alone,	  APAP	  overdose	   is	  responsible	  for	  approximately	  30,000	  hospitalizations	  and	  300	  
deaths	  annually	   (Yoon	  et	  al.,	  2016).	  A	   therapeutic	  dose	  of	  APAP	   is	  mostly	  metabolized	   in	   the	  
liver	   via	   phase	   II	   glucuronidation	   and	   sulfation	   reactions,	  which	   produce	   conjugates	   that	   are	  
easily	   excreted	   into	   the	   blood	   and	   bile.	   The	   fraction	   of	   the	   APAP	   dose	   that	   remains	  
unconjugated	   can	   be	   bioactivated	   into	   the	   highly	   reactive	   metabolite	   N-­‐acetyl-­‐para-­‐benzo-­‐
quinone	   imine	   (NAPQI)	   by	   cytochrome	   P450	   enzymes.	   The	   NAPQI	   that	   is	   formed	   is	   then	  
scavenged	   and	   detoxified	   by	   intracellular	   stores	   of	   glutathione	   (GSH)	   before	   being	   excreted	  
(Yoon	   et	   al.,	   2016).	   In	   cases	   of	   APAP	   overdose,	   the	   phase	   II	   conjugation	   reactions	   become	  
saturated	  and	  cytochrome	  P450	  enzymes	  metabolize	  a	  larger	  portion	  of	  the	  parent	  APAP.	  The	  
excess	   NAPQI	   that	   is	   produced	   depletes	   GSH	   stores,	   allowing	   free	   NAPQI	   to	   form	   protein	  
adducts,	  which	  causes	  cellular	  oxidative	  stress,	  formation	  of	  reactive	  oxygen	  species	  (ROS)	  and	  
eventually	  necrosis	  of	  centrilobular	  hepatocytes	  (McGill	  et	  al.,	  2012).	  	  
	   Oxidative	  stress,	  such	  as	  through	  the	  formation	  of	  ROS,	  is	  a	  common	  occurrence	  in	  the	  
liver	  due	  to	  the	  large	  number	  of	  mitochondria	  present	  in	  hepatocytes,	  as	  well	  as	  a	  function	  of	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the	   liver’s	  oxidative	  metabolism.	  Large	   levels	  of	  oxidative	  stress	  have	   the	  potential	   to	  disrupt	  
cellular	   homeostasis,	   resulting	   in	   cellular	   necrosis	   if	   ROS	   are	   not	   neutralized	   (Jaeschke	   and	  
Ramachandran,	   2011).	   For	   this	   reason,	   it	   is	   crucial	   for	   the	   liver	   to	   possess	  mechanisms	   that	  
counteract	  the	  metabolic	  generation	  of	  reactive	  intermediates.	  
In	   the	   liver,	  heightened	   levels	  of	  oxidative	   stress	  elicit	   an	  antioxidant	   response,	  which	  
serves	  to	  prevent	  cell	  death	  through	  reduction	  of	  cellular	  oxidative	  stress.	  A	  major	  regulator	  of	  
the	  antioxidant	  response	  is	  the	  transcription	  factor	  Nuclear	  factor	  erythroid	  2-­‐related	  factor	  2	  
(Nrf2).	  A	  positive	  linear	  relationship	  exists	  between	  APAP	  dosing	  and	  the	  accumulation	  of	  Nrf2	  
in	   the	   nucleus	   of	   mouse	   hepatocytes.	   Nuclear	   accumulation	   of	   Nrf2	   is	   accompanied	   by	   an	  
increase	   in	   Nrf2	   activity,	   as	   indicated	   by	   the	   increased	  mRNA	   expression	   of	   Nrf2-­‐dependent	  
genes	  (Aleksunes,	  2006;	  Goldring	  et	  al.,	  2004).	  Nrf2	  acts	  in	  the	  activation	  and	  regulation	  of	  the	  
cellular	   response	   to	  oxidative	  stress.	   It	  does	   this	  by	   regulating	   the	   transcription	  of	  a	   series	  of	  
antioxidant-­‐response	  genes,	  which	  help	  regulate	  cell	  survival	  (Jaramillo	  and	  Zhang,	  2013).	  Nrf2	  
is	  a	  member	  of	  the	  cap	  “n”	  collar	  basic	  leucine	  zipper	  family	  and	  is	  regulated	  by	  the	  E3	  ubiquitin	  
ligase	  Kelch-­‐like	  ECH-­‐associated	  protein	  1	   (Keap1).	   In	  normal	  conditions,	  or	  absence	  of	  a	  pro-­‐
oxidant	  state,	  Nrf2	  is	  sequestered	  and	  ubiquinated	  in	  the	  cytosol	  through	  the	  actions	  of	  Keap1.	  
Ubiquitination	   marks	   Nrf2	   for	   rapid	   proteasomal	   degradation.	   In	   the	   presence	   of	   reactive	  
oxygen	   species	   (ROS),	  however,	  Keap1	   Is	  prevented	   from	  sequestering	  Nrf2,	  allowing	  Nrf2	   to	  
accumulate	   in	  the	  cytosol	  before	   its	  translocation	  to	  the	  nucleus.	  Once	  in	  the	  nucleus,	  Nrf2	   is	  
able	  to	  bind	  to	  antioxidant	  response	  elements	  (ARE)	  in	  the	  promoter	  of	  target	  genes,	  enabling	  
transcriptional	  regulation	  of	  a	  series	  of	  genes	  involved	  in	  the	  antioxidant	  response	  (Watai	  et	  al.,	  
2007).	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   The	   protective	   role	   of	   Nrf2	   against	   APAP-­‐induced	   hepatotoxicity	   has	   been	   well	  
demonstrated	  in	  models	  of	  increased	  Nrf2	  activation	  using	  Keap1-­‐null	  mice	  and	  in	  Nrf2	  loss-­‐of-­‐
function	  models	  using	  Nrf2-­‐null	  mice.	  Hepatocyte-­‐specific	  knockout	  of	  Keap1	  results	  in	  elevated	  
levels	  of	  Nrf2	  in	  the	  liver	  and	  increased	  nuclear	  accumulation.	  There	  is	  also	  increased	  activity	  of	  
Nrf2	   as	   illustrated	   by	   increased	   mRNA	   expression	   of	   the	   Nrf2-­‐dependent	   genes	  
NAD(P)H:quinone	   oxidoreductase	   1	   (Nqo1)	   and	   glutamate-­‐cysteine	   ligase	   catalytic	   subunit	  
(Gclc)	  among	  others	   (Okawa	  et	  al.,	  2006).	  Nqo1	  acts	   to	  decrease	  oxidative	  stress	  by	   reducing	  
quinones	   to	   hydroquinones,	   preventing	   the	   formation	   of	   semiquinone	   radical	   intermediates	  
(Atia	   et	   al.,	   2014).	   Gclc	   is	   one	   of	   two	   subunits	   that	  make	   up	   glutamate-­‐cysteine	   ligase	   (Gcl),	  
which	  catalyzes	   the	  rate-­‐limiting	  step	  of	  GSH	  synthesis.	  The	   formation	  of	  GSH	  helps	  decrease	  
oxidative	  stress	  through	  the	  scavenging	  of	  free	  radicals	  and	  other	  reactive	  intermediates	  in	  the	  
cell	  (Gorrini	  et	  al.,	  2013).	  The	  elevated	  levels	  of	  Nqo1,	  Gclc	  and	  other	  Nrf2	  target	  genes	  in	  the	  
conditional	  Keap1-­‐null	  mice	  allow	  these	  mice	  to	  better	  tolerate	  doses	  of	  APAP	  that	  are	  highly	  
toxic	  to	  wild	  type	  mice.	  In	  fact,	  at	  the	  doses	  of	  APAP	  tested,	  Keap1-­‐null	  mice	  exhibited	  minimal	  
evidence	   of	   liver	   injury	   (Okawa	   et	   al.,	   2006).	   At	   the	   other	   end	   of	   the	   spectrum,	  whole	   body	  
knockout	   of	  murine	   Nrf2	   results	   in	   heightened	   susceptibility	   to	   APAP	   hepatotoxicity.	   In	   fact,	  
doses	   that	   are	   typically	   nonlethal	   to	   wild	   type	   mice,	   cause	   high	   mortality	   rates	   when	  
administered	  to	  Nrf2-­‐null	  mice.	  This	  could	  be	  due	  to	  the	  significantly	  lower	  intracellular	  stores	  
of	   GSH	   and	   lower	   basal	   expression	   of	   multiple	   antioxidant	   genes	   observed	   in	   these	   mice	  
(Aleksunes	  et	  al.,	  2008;	  Chan	  et	  al.,	  2001).	  
Activation	  of	  Pparα	  in	  mice	  with	  peroxisome	  proliferator	  treatment	  prior	  to	  APAP	  dosing	  
also	  provides	  protection	  against	  APAP	  hepatotoxicity	  (Chen	  et	  al.,	  2000;	  Manautou	  et	  al.,	  1994,	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1996).	   The	   peroxisome-­‐proliferator	   activated	   receptors	   (Ppars)	   are	   a	   family	   of	   ligand-­‐
dependent	   nuclear	   receptors,	   which	   bind	   to	   a	   peroxisome	   proliferator	   response	   elements	  
(PPREs)	  in	  the	  promoter	  of	  target	  genes	  and	  regulate	  the	  expression	  of	  these	  genes.	  In	  order	  to	  
bind	  the	  PPREs,	  Ppars	  form	  a	  heterodimer	  complex	  in	  the	  nucleus	  with	  the	  retinoid	  X	  receptor	  
(Rxr).	  In	  the	  absence	  of	  ligand	  the	  heterodimer	  forms	  a	  complex	  with	  co-­‐repressor	  proteins	  that	  
prevent	  DNA	  binding.	  The	  binding	  of	  a	  Ppar-­‐specific	  ligand	  allows	  the	  heterodimer	  to	  dissociate	  
from	   these	   co-­‐repressor	   proteins	   and	   enables	   association	  with	   co-­‐activator	   proteins,	   such	   as	  
Pparγ	   coactivator-­‐1α	   (Pgc1α).	   Co-­‐activator	   proteins	   are	   necessary	   for	   the	   association	   of	   a	  
transcription-­‐initiation	  complex	  with	  the	  heterodimer.	  This	  heterodimer	  complex	  is	  able	  to	  bind	  
DNA	  and	  induce	  transcription	  of	  target	  genes	  (Kersten,	  2014).	  	  
There	  are	   three	  different	  members	  of	   the	  Ppar	   family	   (α,	  β/δ	  and	  γ).	   Pparα	   regulates	  
proteins	   that	   act	   to	   release,	  uptake	  or	   transport	   fatty	   acids	   (FAs)	   and	  also	   regulates	  proteins	  
involved	  in	  FA	  β-­‐oxidation.	  Activation	  of	  Pparα,	  in	  response	  to	  factors	  such	  as	  fasting	  or	  fibrate	  
drug	  dosing,	  results	  in	  increased	  cellular	  uptake	  of	  FAs	  and	  a	  decreased	  inflammatory	  response	  
(Delerive,	   2001).	   Pparγ	   is	   involved	   in	   FA	   metabolism,	   glucose	   storage	   and	   adipocyte	  
differentiation.	   Activation	   of	   Pparγ	   limits	   cellular	   proliferation	   and	   migration,	   as	   a	   way	   to	  
conserve	   cellular	   energy	   (Tyagi	   et	   al.,	   2011).	   Pparβ/δ	   also	   acts	   in	   the	   regulation	   of	   genes	  
involved	  in	  FA	  catabolism,	  but	  is	  not	  as	  well	  studied	  as	  the	  other	  Ppars	  (Tyagi	  et	  al.,	  2011).	  	  
The	   hepatoprotective	   role	   of	   Pparα	   has	   been	   addressed	   using	   models	   of	   Pparα	  
activation	  through	  peroxisome	  proliferator	  dosing	  and	  in	  mice	  genetically	  deficient	  in	  Pparα.	  A	  
commonly	   used	   method	   for	   activating	   Pparα	   in	   rodents	   is	   through	   dosing	   with	   a	   class	   of	  
chemicals	  known	  as	  peroxisome	  proliferators.	  The	  fibrates	  are	  a	  group	  of	  hypolipidermic	  drugs,	  
	   38	  
originally	   used	   in	   the	   treatment	   of	   hypercholesterolemia,	   that	   were	   discovered	   to	   cause	  
peroxisome	   proliferation	   in	   rodents.	   Clinically,	   fibrate-­‐type	   drugs	   act	   to	   decrease	   FA	   and	  
triglyceride	  levels	  through	  activation	  of	  peroxisomal	  β-­‐oxidation	  (Pahan,	  2006).	  Clofibrate	  (CFB),	  
the	  first	  of	  the	  fibrate-­‐type	  drugs,	  dosed	  daily	  in	  CD-­‐1	  mice	  for	  ten	  days	  affords	  near	  complete	  
protection	   against	   APAP	   hepatotoxicity.	   This	   could	   be	   due	   to	   the	   increased	   intracellular	  GSH	  
stores,	   lower	  levels	  of	  GSH	  depletion	  and	  decreased	  APAP	  protein	  adduct	  formation	  observed	  
in	   CFB	   pretreated	   mice,	   compared	   to	   vehicle	   pretreated	   controls	   also	   receiving	   APAP	  
(Manautou	   et	   al.,	   1994).	   In	   order	   to	   determine	   if	   the	   protective	   effect	   of	   CFB	   was	   Pparα-­‐
dependent,	   Chen	   et	   al.	   (2000)	   examined	   the	   susceptibility	   of	   Pparα-­‐null	   mice	   to	   APAP	  
hepatotoxicity	   following	  CFB	  pretreatment.	  Unlike	  wild	  type	  mice,	  Pparα-­‐null	  mice	  pretreated	  
with	  CFB	  were	  not	  protected	  from	  APAP	  hepatotoxicity,	  demonstrating	  that	  the	  mechanism	  of	  
CFB-­‐mediated	  protection	  is	  dependent	  on	  Pparα	  presence	  and	  activation	  (Chen	  et	  al.,	  2000).	  
Pretreatment	   with	   just	   a	   single	   dose	   of	   CFB	   was	   demonstrated	   to	   partially	   protect	  
against	  APAP	  toxicity.	  The	  mode	  of	  protection,	  however,	  appears	  to	  differ	  from	  that	  observed	  
in	   the	   ten-­‐day	   pretreatment	  model.	  Unlike	   repeated	   CFB	   dosing,	   a	   single	   CFB	   dose	   does	   not	  
alter	   the	   initial	   GSH	   depletion	   or	   level	   of	   protein	   adducts	   formed	   following	   APAP	   challenge.	  
Covalent	   binding	   is	   necessary,	   but	   not	   sufficient,	   for	   APAP-­‐induced	   hepatotoxicity.	   Since	   the	  
single	  dose	  model	  of	  CFB	  pretreatment	  does	  not	  affect	  hepatic	  covalent	  binding	  of	  APAP,	   it	   is	  
believed	   that	   partial	   protection	   is	   mediated	   through	   disruption	   of	   later	   oxidative	   events	  
(Manautou	  et	  al.,	  1996).	  	  
	   Activation	  of	  Nrf2	  and	  Pparα	  in	  mice	  act	  to	  protect	  against	  toxic	  APAP	  insult.	  However,	  it	  
is	   unknown	   whether	   these	   two	   pathways	   interact	   with	   one	   another	   in	   mediating	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hepatoprotection.	  Direct	  binding	  of	  Nrf2	  to	  the	  promoter	  of	  Rxrα	  and	  Pparγ	  at	  ARE	  consensus	  
sites	  has	  been	  described	  (Cho	  et	  al.,	  2010;	  Chorley	  et	  al.,	  2012).	  The	  interaction	  between	  Nrf2	  
and	  Rxrα	  appears	  to	  occur	  through	  a	  feedback	  loop,	  with	  increased	  Nrf2	  activation	  promoting	  
Rxrα	  expression	  and	  increased	  Rxrα	  expression	  inhibiting	  Nrf2-­‐mediated	  transcription	  (Chorley	  
et	  al.,	  2012;	  Wang	  et	  al.,	  2013).	  As	  for	  Pparγ,	  the	  upregulation	  of	  Pparγ	  in	  response	  to	  hyperoxia	  
in	   the	   lungs	   and	   during	   adipogenesis	   appears	   to	   be	   dependent	   on	   Nrf2	   expression	   and	   its	  
binding	   to	   the	  Pparγ	  promoter	   (Cho	  et	  al.,	  2010;	  Pi	  et	  al.,	  2010).	  Evidence	  suggests	   that	  Nrf2	  
may	  interact	  with	  Pparα,	  however,	  a	  mechanism	  is	  yet	  to	  be	  determined.	  
As	  a	  subset	  to	  a	  study	  by	  Anderson	  et	  al.	  (2004)	  on	  the	  role	  of	  Pparα	  in	  the	  regulation	  of	  
proteome	   maintenance	   genes,	   wild	   type	   and	   Nrf2-­‐null	   mice	   were	   treated	   with	   the	   Pparα-­‐
activator	  WY-­‐14,643	  for	  seven	  days.	  The	  authors	  analyzed	  the	  mRNA	  expression	  of	  a	  series	  of	  
stress	  modifier	  genes	   to	  determine	  whether	  Nrf2	  was	   involved	   in	   their	   regulation.	  Pparα	  and	  
several	  Pparα-­‐target	  genes	  were	  also	  included	  in	  the	  mRNA	  analysis,	  most	  likely	  to	  show	  Pparα	  
was	  being	  activated	  by	  WY-­‐14,643.	  Increased	  mRNA	  expression	  of	  Pparα	  and	  Pparα-­‐dependent	  
genes	  was	  observed	   in	  both	   genotypes.	   The	   increase	   in	  mRNA	  expression	  was	  higher	   in	  WY-­‐
14,643	  treated	  Nrf2-­‐null	  mice	  compared	  to	  all	  other	  treatment	  groups	  (Anderson	  et	  al.,	  2004).	  
In	   another	   study,	  wild	   type	   and	  Nrf2-­‐null	  mice	  were	   fasted	   as	   a	  means	  of	   inducing	  oxidative	  
stress	   in	   mouse	   livers.	   Following	   a	   24-­‐hour	   fast,	   mRNA	   expression	   for	   the	   Ppar	   co-­‐activator	  
protein	  Pgc1α	  was	  elevated	  in	  both	  genotypes,	  with	  expression	  being	  higher	  in	  Nrf2-­‐null	  mice	  
(Zhang	  et	  al.,	  2013).	  Pparα	  activation	  in	  mouse	  liver	  by	  FAs	  has	  been	  reported	  following	  fasting	  
(Bouwens	   et	   al.,	   2007).	   Analysis	   of	   Pgc1α	   expression	   following	   chemically	   induced	   Pparα	  
activation,	  however,	  has	  not	  been	  well	  studied	  in	  wild	  type	  and	  Nrf2-­‐null	  mouse	  liver.	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Both	  Nrf2	  and	  Pparα	  regulate	  genes	  involved	  in	  the	  anti-­‐inflammatory	  response	  and	  in	  
the	   response	   to	   chemically	   induced	   oxidative	   stress.	   An	   interaction	   between	   the	   two	  would	  
most	   likely	   not	   be	   direct	   since	   there	   is	   no	   indication	   of	   direct	   binding	   between	   the	   two	  
transcription	   factors.	  The	  discovery	  of	  a	  potential	   interaction	  between	  Nrf2	  and	  Pparα	  would	  
provide	   new	   insights	   into	   how	   these	   two	   transcription	   factors	   coordinately	   regulate	   gene	  
expression	   in	   response	   to	   xenobiotics	   that	   induce	   oxidative	   stress	   and	   on	   adaptive	   response	  
that	   confer	   tolerance	   to	   toxicants.	   Furthermore,	   it	   may	   provide	   leads	   on	   novel	   therapeutic	  
targets	  for	  the	  treatment	  or	  prevention	  of	  drug	  induced	  liver	  injury.	  In	  order	  to	  determine	  if	  a	  
loss	  of	  Nrf2	  function	  alters	  the	  ability	  of	  fibrate-­‐type	  drugs	  to	  activate	  Pparα,	  wild	  type	  and	  Nrf2	  
knockout	  mice	  were	   treated	   for	   five	   days	  with	   250mg/kg	   of	   CFB.	   This	   study	   also	   determines	  
whether	  or	  not	  Nrf2	  regulates	  expression	  of	  Pparγ	  and	  Rxrα	  in	  mouse	  liver.	  Liver	  samples	  from	  
CFB-­‐treated	   wild	   type	   and	   Nrf2-­‐null	   mice	   were	   used	   to	   analyze	   mRNA	   expression	   of	   Pparα,	  
Pparγ,	  Rxrα,	  Nrf2,	  Pgc1α	  and	  their	  target	  genes.	  Results	  of	  mRNA	  expression	  analysis	   indicate	  
that	   Nrf2-­‐null	  mice	   are	  more	   susceptible	   to	   Pparα	   activation	   by	   the	   peroxisome	   proliferator	  
CFB,	  possibly	  through	  increased	  expression	  of	  Pgc1α.	  
A	  follow	  up	  study	  was	  performed	  in	  order	  to	  determine	   if	  CFB	  pretreatment	   is	  able	  to	  
protect	   Nrf2-­‐null	  mice	   against	   a	   toxic	   dose	   of	   APAP.	   Nrf2-­‐null	  mice	  were	   pretreated	   for	   five	  
days	  with	  250mg/kg	  of	   the	   fibrate	  drug	  CFB	  and	  challenged	  on	  day	   six	  with	  300mg/kg	  APAP.	  
Analysis	   of	   serum	   alanine	   aminotransferase	   (ALT)	   activity	   and	   hepatic	   non-­‐protein	   sulfhydryl	  
(NPSH)	  content	  suggests	  that	  Pparα	  activation	  also	  has	  the	  potential	  to	  partially	  protect	  against	  
oxidative	  stress	  in	  Nrf2-­‐null	  mice,	  as	  we	  have	  previously	  shown	  in	  wild	  type	  mice.	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2.3	  Materials	  and	  Methods:	  
Chemicals.	   Acetaminophen	   (APAP),	   Clofibrate	   (CFB)	   and	   corn	   oil	   (CO)	   were	   purchased	   from	  
Sigma	  Aldrich	  (St.	  Louis,	  MO).	  All	  of	  the	  other	  reagents	  used	  were	  commercially	  available	  and	  of	  
reagent	  grade	  or	  better.	  
	  
Treatment	   of	   Animals.	   Male	   C57BL/6J	   mice	   were	   purchased	   from	   Jackson	   Laboratories	   (Bar	  
Harbor,	  ME)	  and	  were	  acclimated	  for	  one	  week	  upon	  arrival.	  Male	  Nrf2-­‐null	  mice	  on	  a	  mixed	  
C57BL/6	  and	  AKR	  background	  were	  bred	  at	  the	  University	  of	  Connecticut.	  Mice	  were	  housed	  in	  
an	   environment	   with	   a	   12-­‐hour	   light/dark	   cycle,	   controlled	   temperature	   and	   controlled	  
humidity.	  Mice	  were	  fed	   laboratory	  rodent	  diet	  (Harlan	  Teklad	  2018,	  Madison,	  WI)	  and	  water	  
ad	   libitum.	   A	  modified	   version	   of	   a	   ten	   day,	   500mg/kg	   CFB	   dosing	  model	  was	   adapted	   from	  
Nicholls-­‐Grzemski	   et	   al.	   (1992)	   due	   to	   the	   inability	   of	   Nrf2-­‐null	  mice	   to	   tolerate	   a	   500mg/kg	  
dose	  of	  CFB	  for	  more	  than	  a	  few	  days.	  Groups	  of	  mice	  (n	  =	  4-­‐5;	  8-­‐10	  weeks)	  received	  daily	  doses	  
of	  either	  vehicle	  (corn	  oil)	  or	  CFB	  (250mg/kg)	  via	  intraperitoneal	  (i.p.)	  injection	  for	  five	  days.	  24	  
hours	  after	  the	  final	  day	  of	  CFB	  dosing,	  blood	  was	  collected	  in	  1.5mL	  microcentrifuge	  tubes	  for	  
ALT	  analysis.	  Livers	  were	  removed	  and	  portions	  were	  either	  snap	  frozen	  in	  liquid	  nitrogen	  and	  
stored	  at	  -­‐80oC	  or	  fixed	  in	  formalin.	  	  
An	   APAP	   challenge	   study	   was	   also	   conducted.	   Groups	   of	   Nrf2-­‐null	   mice	   (n=3-­‐5;	   8-­‐12	  
weeks)	  were	  dosed	  i.p.	  for	  five	  days	  with	  either	  CFB	  or	  vehicle.	  At	  the	  end	  of	  day	  five	  mice	  were	  
fasted	  overnight.	  On	  day	  six,	  they	  were	  given	  a	  challenge	  dose	  of	  either	  vehicle	  (50%	  propylene	  
glycol;	  5mL/kg	  i.p.)	  or	  APAP	  (300mg/kg).	  Typically	  a	  dose	  of	  at	  least	  400mg/kg	  APAP	  is	  used	  in	  
wild	   type	   mice,	   however,	   Nrf2-­‐null	   mice	   have	   increased	   susceptibility	   to	   APAP	   toxicity,	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therefore	   the	   dose	   was	   lowered	   to	   300mg/kg	   APAP	   to	   reduce	   the	   possibility	   of	   lethality	  
(Aleksunes	  et	  al.,	  2008).	  Food	  was	  returned	  8	  hours	  after	  dosing.	  24	  hours	  after	  APAP	  dosing,	  
blood	  was	  collected	  in	  1.5mL	  microcentrifuge	  tubes	  for	  ALT	  analysis.	  Livers	  were	  removed	  and	  
portions	  were	   either	   snap	   frozen	   in	   liquid	   nitrogen	   and	   stored	   at	   -­‐80oC,	   fixed	   in	   formalin	   or	  
placed	   in	   trichloroacetic	   acid	   (TCA)	  buffer	   (5%	  TCA	   in	  10-­‐3M	  EDTA)	   for	  non-­‐protein	   sulfhydryl	  
(NPSH)	   analysis.	   All	   animal	   studies	  were	   conducted	   in	   accordance	  with	   the	   standards	   of	   the	  
National	  Institutes	  of	  Health	  and	  the	  Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals.	  Studies	  
were	  approved	  by	  the	  University	  of	  Connecticut	  Institutional	  Animal	  Care	  and	  Use	  Committee	  
(IACUC	  Protocol	  no.	  A15-­‐041).	  	  
	  
Alanine	   Aminotransferase	   (ALT)	   Activity	   Assay.	   Hepatotoxicity	   was	   determined	   by	  measuring	  
ALT	   activity	   in	   serum	   samples	   using	   an	   Infinity	   ALT	   (GPT)	   Reagent	   from	   Thermo	   Scientific	  
(Waltham,	  MA)	  using	  the	  recommendations	  of	  the	  manufacturer.	  Whole	  blood	  was	  allowed	  to	  
clot	  for	  30-­‐minutes	  and	  serum	  was	  isolated	  following	  a	  15-­‐minute	  spin	  at	  2000	  x	  g	  in	  a	  tabletop	  
centrifuge.	  Samples	  were	  read	  on	  a	  BioTek	  PowerwaveX	  96-­‐well	  plate	  reader	  (Winooski,	  VT).	  	  
Histology.	   Liver	   samples	   were	   fixed	   in	   10%	   zinc	   formalin	   before	   paraffin	   embedding.	   5μm	  
sections	   from	   the	   paraffin	   embedded	   samples	  were	   stained	  with	   hematoxylin	   and	   eosin	   and	  
observed	  using	  light	  microscopy	  for	  the	  presence	  of	  hepatomegaly,	  hepatocellular	  necrosis	  and	  
other	  alterations	  to	  liver	  structure.	  	  
	  
RNA	  Isolation	  and	  Quantitative	  Real-­‐Time	  Polymerase	  Chain	  Reaction	  (qRT-­‐PCR).	  Total	  RNA	  was	  
extracted	   from	   mouse	   liver	   samples	   using	   TRIzol	   reagent	   (Life	   Technologies,	   Carlsbad,	   CA)	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according	   to	   the	   manufacturer’s	   recommendations.	   Total	   RNA	   was	   then	   reverse-­‐transcribed	  
into	   cDNA	   using	   an	   iScript	   cDNA	   synthesis	   kit	   (BioRad,	   Hercules,	   CA).	   qRT-­‐PCR	  was	   run	   on	   a	  
7500	  Fast	  Real-­‐Time	  PCR	  System	  (Applied	  Biosystems,	  Foster	  City,	  CA)	  using	  SYBR	  green	  master	  
mix	   (BioRad,	   Hercules,	   CA)	   and	   species-­‐specific	   primers	   for	   each	   gene	   (Table	   2.1).	   mRNA	  
expression	  was	  quantified	  using	  the	  ΔΔCT	  method	  and	  was	  normalized	  to	  β-­‐actin.	  	  
	  
Protein	   Isolation	  and	  Western	  Blot	  Analysis.	  Portions	  of	   livers,	   snap	   frozen	   in	   liquid	  nitrogen,	  
were	   homogenized	   in	   sucrose-­‐Tris	   (ST)	   buffer	   (150mM	   sucrose,	   10mM	   Tris-­‐HCl,	   pH	   7.5)	  
containing	  1%	  Halt	  protease	  inhibitor	  cocktail	  (100X;	  Thermo	  Scientific,	  Waltham,	  MA).	  Protein	  
concentrations	  of	  whole	  liver	  and	  nuclear	  homogenates	  were	  assayed	  using	  BioRad	  DC	  protein	  
assay	   reagents	   (BioRad,	   Hercules,	   CA),	   and	   using	   dilutions	   of	   bovine	   serum	   albumin	   (BSA)	  
(Sigma-­‐Aldrich,	   St.	   Louis,	   MO)	   to	   develop	   a	   standard	   curve.	   Whole	   liver	   and	   nuclear	  
homogenates	  were	  diluted	  1:1	  with	  2x	  Kaman	  buffer	  (2.3%	  sodium	  dodecyl	  sulfate	  (SDS),	  10%	  
Glycerol,	  5%	  2-­‐Mercaptoethanol,	  62.5mM	  Tris-­‐HCl)	  and	  boiled	  for	  5	  minutes	  at	  95oC	  before	  gel	  
loading.	  Protein	  samples	  were	  resolved	  with	  gel	  electrophoresis	  using	  polyacrylamide	  gels	  (10%	  
resolving,	  4%	  stacking;	  run	  for	  120min	  at	  120v;	  transferred	  for	  90min	  at	  105v)	  and	  trans-­‐blotted	  
onto	   Polyvinylidene	   Fluoride	   (PVDF)	   membranes	   (Micron	   Separations,	   Westboro,	   MA)	  
Membranes	   were	   blocked	   overnight	   in	   5%	   non-­‐fat	   dry	   milk	   dissolved	   in	   Tris-­‐buffered	   saline	  
containing	   .1%	  Tween-­‐20	  (TBS-­‐T,	  pH	  7.4).	  Membranes	  were	   incubated	  overnight	  with	  primary	  
antibody	   diluted	   in	   blocking	   buffer,	   followed	  by	   a	  wash	  with	   TBS-­‐T.	   The	   appropriate	   primary	  
antibody	  was	  used	  for	  Vnn1	  (Ab96171;	  Abcam,	  Cambridge,	  MA),	  β-­‐actin	  (Ab8227;	  Abcam),	  and	  
Nqo1	   (ab2346;	   Abcam).	   Membranes	   were	   then	   incubated	   for	   2	   hours	   with	   species-­‐specific	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peroxidase-­‐labeled	   secondary	   antibodies	   (Sigma-­‐Aldrich,	   St.	   Loius,	   MO)	   diluted	   in	   blocking	  
buffer.	   After	   another	   wash	   period	   in	   TBS-­‐T,	   blots	   were	   coated	   in	   Immobilin	   Western	  
Chemiluminesent	  HRP	   Substrate	   (Millipore,	   Billerica,	  MA)	   for	   1	  minute.	   This	  was	   followed	  by	  
exposure	   to	   X-­‐ray	   film.	   Protein	   expression	   was	   quantified,	   using	   ImageJ	   image	   processing	  
software,	  and	  normalized	  to	  β-­‐actin	  (whole	  liver).	  
	  
Non-­‐Protein	  Sulfhydryl	  Assay.	  The	  total	  concentration	  of	  GSH	   in	   the	   liver	  was	  quantified	   from	  
the	  supernatant	  of	  a	  20%	  liver	  homogenates	  in	  5%	  TCA	  in	  3mM	  EDTA.	  The	  colorimetric	  assay	  of	  
Ellman	  was	  used	   for	   quantifying	  NPSH,	   as	   adapted	  by	  Manautou	  et	   al.	   (1994)	   (Ellman,	   1959;	  
Manautou	   et	   al.,	   1994).	   Samples	   were	   read	   on	   a	   BioTek	   PowerwaveX	   96-­‐well	   plate	   reader	  
(Winooski,	  VT)	  at	  490nm.	  The	  levels	  of	  NPSH	  in	  liver	  were	  determined	  through	  comparison	  to	  a	  
GSH	  standard	  curve.	  
	  
Statistical	   Analysis.	   The	   statistical	   significance	   between	   groups	   was	   determined	   using	   the	  
Student’s	  t-­‐test	  or	  one-­‐way	  ANOVA	  with	  the	  Newman-­‐Keuls	  post	  hoc	  test.	  The	  Student’s	  t-­‐test	  
was	   used	   to	   compare	   means	   of	   two	   different	   treatment	   groups	   and	   ANOVA	   was	   used	   to	  
compare	  the	  means	  of	  more	  than	  two	  treatment	  groups	  normally	  distributed	  with	  a	  common	  
variance.	  Statistical	  analyses	  were	  performed	  using	  GraphPad	  Prism	  version	  4.00	  for	  Windows	  
(GraphPad	  Software	  Inc.,	  San	  Diego,	  CA).	  Data	  are	  presented	  as	  the	  mean	  ±	  standard	  error	  of	  
the	  mean	  (SEM),	  with	  p	  <	  0.05	  considered	  statistically	  significant.	  	  
	  
2.4	  Results:	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Clofibrate	  increases	  liver	  to	  bodyweight	  ratio	  in	  Nrf2	  but	  not	  wild	  type	  mice	  
	   In	  a	  ten	  day	  model	  of	  500mg/kg	  CFB	  dosing,	  wild	  type	  mice	  receiving	  CFB	  had	  greater	  
liver	   to	   bodyweight	   ratio	   than	  mice	   receiving	   only	   vehicle	   (Manautou	   et	   al.,	   1994).	  With	   the	  
reduced	   dose	   (250mg/kg	   CFB)	   and	   reduced	   duration	   of	   dosing	   (five	   days)	   employed	   in	   the	  
current	  study,	  there	  were	  no	  significant	  changes	  in	  liver	  to	  bodyweight	  ratios	  in	  wild	  type	  mice	  
treated	  with	   CFB	   (Figure	   2.1a).	   This	   suggests	   that	   this	   alternative	   CFB	   dosing	   regimen	   is	   not	  
sufficient	   to	   produce	   the	   marked	   hepatomegaly	   previously	   reported	   in	   rodents.	   Histological	  
analysis	   of	   vehicle	   and	   CFB-­‐treated	   wild	   type	   mouse	   livers	   did	   not	   reveal	   any	   obvious	  
morphological	  differences	  in	  hepatocytes	  between	  the	  two	  treatment	  groups	  (data	  not	  shown).	  
However,	  the	  basal	   liver	  to	  bodyweight	  ratio	   in	  Nrf2-­‐null	  mice	  was	  reduced	  compared	  to	  wild	  
types.	  This	  finding	  has	  been	  previously	  reported	  and	  could	  possibly	  be	  due	  to	  decreased	  rates	  
of	   hepatocellular	   proliferation	   in	   Nrf2-­‐null	   mice	   (Beyer	   et	   al.,	   2008).	   Although	   the	   liver	   to	  
bodyweight	   ratio	   was	   unchanged	   in	   wild	   type	   mice	   following	   CFB	   treatment,	   a	   significant	  
increase	   was	   observed	   in	   CFB-­‐treated	   Nrf2-­‐null	   mice.	   The	   drug-­‐induced	   increase	   in	   liver	   to	  
bodyweight	   ratio	   in	   null	  mice	   does	   not	   seem	   to	   be	   accompanied	   by	   hepatocellular	   injury	   or	  
inflammation,	   since	  no	  ALT	  elevations	  were	  observed	   (Figure	  2.1b).	   Furthermore,	  histological	  
analysis	  of	  vehicle	  and	  CFB-­‐treated	  Nrf2-­‐null	  mouse	  livers	  did	  not	  reveal	  the	  presence	  of	  injury	  
or	   inflammation	   in	  either	   treatment	  group	   (data	  not	   shown).	   It	   is	  possible	   that	   the	   increased	  
liver	   to	   bodyweight	   ratio	   observed	   in	   the	   CFB-­‐treated	   Nrf2-­‐null	   mice	   may	   be	   due	   to	  
hepatocellular	  hyperplasia	  or	  enlargement	  of	  hepatocytes.	  Treatment	  of	  mice	  for	  five	  days	  with	  
250mg/kg	   CFB	   does	   not	   seem	   to	   be	   sufficient	   to	   cause	   the	   hepatomegaly	  
observed	  in	  wild	  type	  mice	  in	  our	  previously	  used	  ten-­‐day	  model.
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Figure	   2.1:	   Liver	   to	   Bodyweight	   Ratio	   and	  ALT	  Activity	  Analysis	   Following	  Clofibrate	   Treatment.	  Livers	  
and	  serum	  were	  isolated	  from	  mice	  24	  hours	  after	  the	  final	  dose	  of	  CFB.	  (A)	  Liver	  to	  bodyweight	  ratio	  is	  
presented	  as	  percent	  of	   total	  body	  weight	  ±	  SEM	  (n=4-­‐5	  animals).	   (B)	  Data	  presented	  as	  mean	  serum	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Nrf2-­‐null	  mice	  have	  increased	  sensitivity	  to	  Pparα	  activation	  	  
	   Nrf2	   and	   Pparα	   have	   both	   been	   linked	   to	   protection	   against	   APAP	   hepatotoxicity.	  
However,	   it	   is	   not	   known	   if	   the	   two	   transcription	   factors	   engage	   in	   crosstalk	   to	  mediate	   this	  
protection.	  Peroxisome	  proliferators	  exert	  their	  effects	  (i.e.	  hepatomegaly,	  hepatic	  peroxisome	  
proliferation)	   through	   activation	   of	   the	   Pparα	   receptor	   in	   mice.	   The	   ability	   of	   peroxisome	  
proliferators,	   such	  as	  CFB,	   to	  activate	  Pparα	   in	   the	  absence	  of	  Nrf2	  has	  not	  been	  extensively	  
studied	  and	  may	  provide	  some	   insight	   into	  whether	  or	  not	   the	  Nrf2	  and	  Pparα	  pathways	  are	  
interconnected	  and	  operating	  in	  a	  coordinated	  manner	  to	  protect	  the	  liver.	  
A	  gene	  array	  study	  on	  CFB-­‐treated	  wild	  type	  and	  Pparα-­‐null	  mouse	  livers	  identified	  the	  
Pparα	  target	  gene	  Vanin1	  (Vnn1)	  as	  being	  heavily	  induced	  by	  CFB	  treatment	  in	  wild	  type	  mice,	  
compared	   to	   vehicle.	   Furthermore,	   analysis	   of	   mRNA	   expression	   revealed	   that	   the	   basal	  
expression	  of	  Vnn1	  is	  significantly	  reduced	  in	  Pparα-­‐null	  mice,	  compared	  to	  wild	  type	  (Moffit	  et	  
al.,	  2007).	  Vnn1	  is	  a	  pantetheinase	  that	  functions	  in	  the	  hydrolysis	  of	  pantetheine	  into	  the	  CoA	  
precursor	   vitamin	   B5	   (pantotheic	   acid)	   and	   the	   antioxidant	   cysteamine	   (Chen	   et	   al.,	   2014).	  
Studies	   in	   Vnn1-­‐null	   mice	   determined	   that	   Vnn1	   is	   involved	   in	   Pparα-­‐mediated	   protection	  
against	   APAP	   hepatotoxicity,	   as	   evidenced	   by	   the	   greater	   susceptibility	   of	   Vnn1-­‐null	  mice	   to	  
APAP	  hepatotoxicity	  (Ferreira	  et	  al.,	  2016).	  Due	  to	   its	   induction	  by	  CFB	  and	  its	   involvement	   in	  
Pparα-­‐mediated	   protection	   against	   APAP	   hepatotoxicity	   (Ferreira	   et	   al.,	   2016;	   Moffit	   et	   al.,	  
2007),	  Vnn1	  expression	  should	  be	  a	  good	  indicator	  of	  potential	  Pparα	  activation	  in	  the	  Nrf2-­‐null	  
mice.	  	  
	   51	  
In	  order	  to	  investigate	  the	  effect	  of	  Nrf2	  knockout	  on	  Pparα	  expression	  and	  activation,	  
qRT-­‐PCR	  was	  performed	  on	  cDNA	  isolated	  from	  vehicle	  and	  CFB-­‐treated	  wild	  type	  and	  Nrf2-­‐null	  
livers.	  mRNA	  expression	  was	  determined	  for	  Pparα,	  Vnn1	  (Vnn1)	  and	  other	  known	  Pparα	  target	  
genes	   (i.e.	   Acyl-­‐CoA	   oxidase	   1	   (Acox1),	   Pyruvate	   dehydrogenase	   kinase	   4	   (Pdk4),	   Cyp4a10).	  
Acox1	  was	  the	  first	  Pparα	  target	  gene	  to	  be	  identified,	  which	  encodes	  the	  enzyme	  involved	  in	  
the	   first	   step	   of	   peroxisomal	   long-­‐chain	   FA	   oxidation	   (Kersten,	   2014).	   Pdk4	   is	   an	   enzyme	  
normally	   activated	   during	   periods	   of	   fasting.	   It	   is	   involved	   in	   switching	   fuel	   sources	   from	  
oxidation	  of	  carbohydrates	  to	  oxidation	  of	  fat	  (Wang	  and	  Sahlin,	  2012).	  Cyp4a10	  is	  a	  member	  of	  
the	   Cyp4a	   subfamily	   of	   cytochrome	   P450s.	   The	   Cyp4a	   subfamily	   is	   expressed	   in	   the	   rough	  
endoplasmic	  reticulum	  in	  the	  liver	  and	  functions	  in	  the	  hydroxylation	  of	  medium	  and	  long	  chain	  
FAs.	  Long	  chain	  FAs	  are	  then	  β-­‐oxidized	  in	  the	  mitochondria	  or	  peroxisomes	  for	  subsequent	  use	  
as	  fuel	  (Nyagode	  et	  al.,	  2014).	  	  	  
	   Our	  results	  indicate	  that	  there	  are	  no	  changes	  in	  basal	  Pparα	  hepatic	  mRNA	  expression	  
between	  wild	  type	  and	  Nrf2-­‐null	  mice,	  or	  between	  vehicle	  and	  CFB-­‐treated	  wild	  type	  mice.	  CFB	  
treatment	  in	  Nrf2-­‐null	  mice	  did	  lead	  to	  a	  significant	  increase	  in	  Pparα	  mRNA	  expression	  (Figure	  
2.2a).	  There	  were	  no	  changes	  in	  the	  basal	  mRNA	  expression	  of	  Vnn1,	  Acox1,	  Pdk4	  and	  Cyp4a10	  
between	  vehicle-­‐treated	  wild	  type	  and	  Nrf2-­‐null	  mice.	  Compared	  to	  vehicle-­‐treated	  controls,	  a	  
significant	   increase	   in	   mRNA	   expression	   was	   observed	   for	   all	   target	   genes	   following	   CFB	  
treatment	  in	  both	  genotypes	  (Figures	  2.2b-­‐e).	  Compared	  to	  all	  other	  treatment	  groups,	  mRNA	  
expression	  for	  Vnn1,	  Pdk4	  and	  Cyp4a10	  was	  significantly	  higher	  in	  CFB-­‐treated	  Nrf2-­‐null	  mice.	  A	  
similar	  trend	  was	  observed	  in	  Acox1	  expression,	  but	  it	  was	  not	  significant.	  These	  data	  indicate	  
that	   CFB-­‐mediated	   Pparα	   activation	   is	   greater	   in	   Nrf2-­‐null	   mice	   than	   in	   wild	   type	   mice.	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Figure	   2.2:	  Hepatic	   Gene	   Expression	   of	   Pparα	   and	   Pparα–Dependent	   Genes.	   qRT-­‐PCR	  was	   performed	  
using	  cDNA	  isolated	  from	  wild-­‐type	  and	  Nrf2-­‐null	  mouse	  livers	  24	  hours	  after	  the	  last	  of	  five	  daily	  doses	  
of	  CFB	  (250mg/kg;	  i.p.).	  (A)	  Gene	  expression	  of	  Pparα.	  (B-­‐E)	  Gene	  expression	  of	  Pparα-­‐dependent	  genes	  
involved	   in	   the	   cellular	   response	   to	   oxidative	   stress	   (Vnn1)	   and	   in	   fatty	   acid	   oxidation	   (Vnn1,	   Acox1,	  
Pdk4	   and	   Cyp4a10).	   Data	   is	   presented	   as	   mean	   gene	   expression	   ±	   SEM	   (n=4-­‐5	   mice).	   Values	   with	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Nrf2-­‐null	  mice	  have	  decreased	  basal	  hepatic	  mRNA	  expression	  of	  Pparγ	  
A	   literature	   search	   to	   determine	   if	   a	   possible	   connection	   between	   Nrf2	   and	   Ppar	  
signaling	  pathways	  has	  already	  been	  established	  revealed	  the	  existence	  of	  such	  a	  connection.	  
Pparγ	  is	  part	  of	  the	  Ppar	  family	  of	  nuclear	  receptors	  and	  acts	  in	  FA	  metabolism,	  glucose	  storage	  
and	  adipocyte	  differentiation.	   It	   is	  highly	  expressed	   in	  adipose	   tissue,	  but	   is	  also	  ubiquitously	  
expressed	   in	  other	   tissue	   types,	   such	  as	   the	   liver.	  CFB-­‐mediated	  activation	  of	  Pparγ	  has	  been	  
reported	  in	  zebrafish	  hepatocytes	  (Ibabe	  et	  al.,	  2005).	  Studies	  of	  acute	  lung	  injury	  in	  Nrf2-­‐null	  
mice	   identified	  an	  ARE	  binding	  site	   for	  Nrf2	   in	   the	  Pparγ	  promoter	  and	  determined	  that	  Nrf2	  
has	   a	   role	   in	   the	   regulation	   of	   Pparγ	   (Cho	   et	   al.,	   2010).	   Another	   group	   of	   investigators	  
discovered	  that	  Nrf2	  is	  important	  for	  regulating	  Pparγ	  expression	  during	  adipogenesis.	  Nrf2-­‐null	  
mice	  exhibited	  impaired	  adipogenesis	  due	  to	  decreased	  mRNA	  and	  protein	  expression	  of	  Pparγ	  
(Pi	   et	   al.,	   2010).	   It	   is	   clear	   that	   Nrf2	   is	   involved	   in	   the	   regulation	   of	   Pparγ,	   however,	   it	   is	  
unknown	  whether	  or	  not	  this	  regulation	  extends	  to	  the	  liver.	  	  
In	  order	  to	  determine	  if	  Nrf2	  affects	  Pparγ	  expression	  in	  the	  liver	  and	  if	  CFB	  treatment	  
influences	  Pparγ	  activation,	  qRT-­‐PCR	  was	  performed	  on	  Pparγ	  and	  Pparγ	  target	  genes,	  such	  as	  
fatty	  acid	  transport	  protein	  1	  (Fatp1;	  Slc27a1),	  lipoprotein	  lipase	  (Lpl),	  glucose	  transporter	  type	  
4	  (Glut4)	  and	  fatty	  acid	  binding	  protein	  4	  (Fabp4).	  These	  genes	  were	  selected	  due	  to	  their	  high	  
levels	   of	   expression	   in	   adipose	   tissue	   and	   their	   roles	   in	   the	   transport	   or	   storage	   of	   FAs	   or	  
glucose.	  Slc27a1	  is	  a	  transport	  protein	  involved	  in	  the	  uptake	  of	  long	  chain	  FAs	  (Guitart	  et	  al.,	  
2014).	  Lpl	  catalyzes	  the	  hydrolysis	  of	  triacylglycerol	  and	  very	  low-­‐density	  lipoproteins	  into	  free	  
FAs.	   These	   free	  FAs	   can	   then	  be	   stored	   in	  adipose	  as	   triacylglycerol	  or	  oxidized	  and	  used	   for	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energy	   (Braun	   and	   Severson,	   1992).	   Glut4	   is	   a	   transport	   protein	   involved	   in	   the	   uptake	   of	  
glucose	  from	  the	  systemic	  circulation	  into	  mainly	  muscle	  and	  adipose	  tissue	  (Huang	  and	  Czech,	  
2007).	   Fabp4	   is	   a	   chaperone	   protein	   for	   FAs	   and	   acts	   to	   transport	   intracellular	   lipids	   to	  
biological	  targets	  (Garin-­‐Shkolnik	  et	  al.,	  2014).	  
	   Basal	  mRNA	  expression	  of	  Pparγ	  was	  significantly	   lower	   in	  Nrf2-­‐null	   compared	   to	  wild	  
type	   mice.	   There	   was	   no	   significant	   alteration	   in	   Pparγ	   mRNA	   expression	   in	   wild	   type	   mice	  
following	   CFB	   treatment;	   while	   the	   CFB-­‐treated	   Nrf2-­‐null	   mice	   exhibited	   similarly	   repressed	  
levels	   of	   Pparγ	  mRNA	   as	   vehicle-­‐treated	   null	   mice	   (Figure	   2.3a).	   Furthermore,	   there	   was	   no	  
change	   in	   the	   basal	   mRNA	   expression	   of	   Slc27a1,	   Lpl,	   Glut4	   or	   Fabp4	   between	   genotypes	  
(Figure	  2.3b-­‐e).	  There	  were	  also	  no	  significant	  changes	   in	  mRNA	  expression	  of	   these	  genes	   in	  
wild	  type	  mice	  treated	  with	  CFB.	  However,	  in	  Nrf2-­‐null	  mice	  receiving	  CFB	  the	  mRNA	  expression	  
of	  Slc27a1,	  Lpl,	  Glut4,	  and	  Fabp4	  was	  significantly	  increased.	  This	  suggests	  that	  the	  expression	  
of	  the	  Pparγ-­‐dependent	  genes	  is	  being	  regulated	  by	  Pparα	  activation.	  Due	  to	  the	  major	  role	  of	  
the	  Ppars	  in	  FA	  metabolism,	  it	  is	  not	  surprising	  that	  there	  is	  a	  degree	  of	  overlap	  between	  genes	  
that	  are	  targeted	  by	  Pparγ	  and	  genes	  that	  are	  targeted	  by	  Pparα.	  Slc27a1,	  Lpl	  and	  Fabp4	  have	  
all	   been	   shown	   to	   be	   upregulated	   by	   Pparα	   activation	   in	   liver	   macrophages	   (Kupffer	   cells)	  
(Rakhshandehroo	  et	  al.,	  2010).	  Despite	  this,	  it	  is	  clear	  that	  the	  lack	  of	  Nrf2	  is	  causing	  a	  decrease	  
in	  the	  basal	  expression	  of	  Pparγ	  mRNA,	  which	  suggests	  that	  Pparγ	  expression	  is	  Nrf2-­‐dependent	  
in	  the	  mouse	  liver.	  	  
	  
Clofibrate	  does	  not	  affect	  the	  expression	  of	  Rxrα	  and	  Rxrα	  target	  genes	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Figure	   2.3:	  Hepatic	  Gene	   Expression	  of	   Pparγ	   and	  Pparγ	   Target	  Genes.	   qRT-­‐PCR	  was	  performed	  using	  
cDNA	  isolated	  from	  wild-­‐type	  and	  Nrf2-­‐null	  mouse	  livers	  24	  hours	  after	  the	  last	  of	  five	  daily	  doses	  of	  CFB	  
(250mg/kg;	  i.p.).	  (A)	  Gene	  expression	  of	  Pparγ.	  (B-­‐E)	  Gene	  expression	  of	  Pparγ	  target	  genes	  involved	  in	  
fatty	   acid	   transport	   (Slc27a1,	   Fabp4),	   lipid	   metabolism	   (Lpl)	   and	   glucose	   transport	   (Glut4).	   Data	   is	  
presented	   as	   mean	   gene	   expression	   ±	   SEM	   (n=4-­‐5	   mice).	   Values	   with	   different	   superscripts	   are	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   Rxrα	  is	  a	  member	  of	  the	  retinoid	  X	  receptor	  (Rxr)	  family	  of	  nuclear	  receptors,	  along	  with	  
Rxrβ,	   and	   Rxrγ.	   The	   Rxr	   family	   acts	   as	   a	   heterodimer	   partner	   for	   many	   nuclear	   receptors,	  
including	   retinoic	   acid	   receptors	   (Rars),	   the	   Ppars,	   vitamin	   D	   receptors	   (Vdr)	   and	   thyroid	  
hormone	  receptors	  (Tr)	  (Mangelsdorf	  et	  al.,	  1992).	  The	  Rxrα	  subtype	  was	  chosen	  for	  analysis	  in	  
mouse	   liver	  due	   to	   its	  high	  expression	   in	   the	   liver,	   kidney,	   intestine	  and	  muscle	   (Pérez	  et	  al.,	  
2012).	  
	   Rxrα	   is	   a	   crucial	   component	   of	   Ppar	   signaling,	   and	   expression	   and	   regulation	   of	   Rxrα	  
could	   have	   direct	   effects	   on	   Ppar	   signaling.	   There	   is	   experimental	   evidence	   supporting	   the	  
regulation	  of	  Rxrα	  by	  Nrf2.	  A	  genome-­‐wide	  binding	  study	  for	  human	  Nrf2	  revealed	  that	  Rxrα	  is	  
an	  ARE-­‐dependent	  target	  of	  Nrf2	  binding.	  Also,	  mRNA	  expression	  of	  Rxrα	  is	   increased	  by	  Nrf2	  
activation	  and	  decreased	  by	  Nrf2	  knockdown	   in	  mouse	  embryonic	   fibroblast	   cells	   (Chorley	  et	  
al.,	   2012).	   It	   appears	   that	   Rxrα	   may	   also	   play	   a	   role	   in	   the	   regulation	   of	   Nrf2	   activity.	  
Overexpression	  of	  Rxrα	  in	  human	  colon	  cancer	  cells	  results	  in	  reduced	  basal	  mRNA	  expression	  
of	  Nrf2-­‐dependent	  genes	  and	  Rxrα	  knockdown	  results	  in	  increased	  basal	  mRNA	  expression	  for	  
these	   genes	   (Wang	   et	   al.,	   2013).	   Altogether	   these	   results	   suggest	   that	   there	   is	   a	   regulatory	  
feedback	  loop	  present	  between	  Nrf2	  and	  Rxrα.	  	  
	   Analysis	   of	   mRNA	   expression	   for	   Rxrα	   and	   Rxrα	   target	   genes,	   such	   as	   Retinoic	   acid	  
receptor	   α	   (Rarα),	   Deiodinase	   1	   (Dio1),	   Cyp2r1,	   and	   Retinol	   binding	   protein	   1	   (Rbp1),	   was	  
performed	  to	  determine	  if	  CFB	  treatment	  or	  loss	  of	  Nrf2	  is	  having	  any	  effect	  on	  Rxrα	  expression	  
or	   activity.	   Rarα	   is	   a	   heterodimer	   partner	   for	   Rxrα.	   The	   Rar-­‐Rxr	   heterodimer	   acts	   in	   the	  
transcriptional	   regulation	   of	   genes	   involved	   in	   cell-­‐cycle	   arrest,	   cell	   differentiation	   and	   cell	  
death	  (Kalitin	  and	  Karamysheva,	  2016).	  Dio1	  is	  the	  enzyme,	  present	  in	  the	  liver,	  responsible	  for	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the	  conversion	  of	  the	  thyroid	  pro-­‐hormone	  thyroxine	  to	  its	  active	  form	  triiodothyronine.	  Dio1	  is	  
a	  target	  gene	  of	  the	  thyroid	  hormone	  receptor,	  which	  forms	  a	  heterodimer	  with	  Rxrα	  (Yu	  and	  
Koenig,	  2006).	  Cyp2r1	  catalyzes	  a	  step	  in	  the	  synthesis	  of	  the	  active	  form	  of	  vitamin	  D.	  Cyp2r1	  is	  
regulated	  by	  the	  vitamin	  D	  receptor,	  which	  forms	  a	  heterodimer	  with	  Rxrα	  (Cheng	  et	  al.,	  2004).	  
Rbp1	   is	  a	   target	  gene	  of	  Rarα	   that	  acts	  as	  a	  chaperone	  protein	   for	   retinol	   (Pierzchalski	  et	  al.,	  
2014).	  
	   Analysis	  of	  Rxrα	  mRNA	  expression	  shows	  no	  changes	  between	  Nrf2-­‐null	  and	  wild	   type	  
mice	  or	  between	  vehicle	  and	  CFB	  treatment	  groups	  (Figure	  2.4a).	  There	  was	  also	  no	  change	  in	  
mRNA	  expression	  of	  Rarα	  or	  Cyp2r1	  between	  genotypes	  or	  treatment	  groups	  (Figure	  2.4b	  and	  
c).	  Basal	  mRNA	  expression	  for	  Dio1	  was	  significantly	  lower	  in	  Nrf2-­‐null	  mouse	  liver	  compared	  to	  
wild	   types.	   However,	   no	   significant	   changes	  were	   observed	   in	   response	   to	   CFB	   treatment	   in	  
either	   genotype	   (Figure	  2.4d).	  Basal	  mRNA	  expression	   for	  Rbp1	  was	   significantly	   increased	   in	  
Nrf2-­‐null	  compared	  to	  wild	  type.	  For	  all	  genes	  tested,	  CFB	  treatment	  in	  both	  genotypes	  did	  not	  
produce	  any	  significant	  changes	  in	  mRNA	  expression	  (Figure	  2.4e).	  Loss	  of	  Nrf2	  appears	  to	  have	  
an	  effect	  on	  the	  expression	  of	  some	  Rxrα	  target	  genes.	  These	  effects	  do	  not	  appear	  to	  be	  due	  to	  
Nrf2-­‐mediated	  changes	   in	  Rxrα	  expression.	  Also,	  CFB	   treatment	  does	  not	  appear	   to	  have	  any	  
effect	  on	  the	  mRNA	  expression	  of	  Rxrα	  or	  its	  target	  genes.	  
	  
Clofibrate	  increases	  the	  mRNA	  expression	  of	  Nrf2	  in	  wild	  type	  mice	  
	   Nrf2	  acts	  to	  regulate	  the	  transcription	  of	  genes	  involved	  in	  protecting	  against	  oxidative	  
stress.	   In	   the	   absence	   of	   Nrf2	   cells	   become	   more	   susceptible	   to	   oxidative	   damage.	   CFB	  
treatment,	   in	   a	   Pparα-­‐dependent	  manner,	   has	   been	   demonstrated	   to	   induce	   the	  mRNA	   and	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Figure	  2.4:	  Hepatic	  Gene	  Expression	  of	  Rxrα	  and	  Rxrα–Dependent	  Genes.	  qRT-­‐PCR	  was	  performed	  using	  
cDNA	  isolated	  from	  wild-­‐type	  and	  Nrf2-­‐null	  mouse	  livers	  24	  hours	  after	  the	  last	  of	  five	  daily	  doses	  of	  CFB	  
(250mg/kg;	   i.p.).	   (A)	   Gene	   expression	   of	   Rxrα.	   (B)	   Gene	   expression	   of	   the	   Rxrα	   heterodimer	   partner	  
Rarα.	   (C-­‐E)	  Gene	  expression	  of	  non-­‐Ppar,	  Rxrα	  heterodimer	   target	  genes	   involved	   in	   thyroid	  hormone	  
activation	   (Dio1),	   vitamin	   D	   metabolism	   (Cyp2r1)	   and	   retinol	   transport	   (Rbp1).	   Data	   is	   presented	   as	  
mean	  gene	  expression	  ±	  SEM	  (n=4-­‐5	  mice).	  Values	  with	  different	  superscripts	  are	  significantly	  different	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protein	  expression	  of	  several	  efflux	  transporters	  that	  are	  targets	  of	  Nrf2	  (Moffit,	  2006).	  In	  order	  
to	  determine	  the	  effect	  of	  CFB	  treatment	  on	  Nrf2	  in	  the	  five	  day	  CFB	  dosing	  mouse	  model,	  qRT-­‐
PCR	   analysis	  was	   performed	   to	   analyze	   the	  mRNA	  expression	  of	  Nrf2	   and	  Nrf2	   target	   genes,	  
such	   as	   glutamate-­‐cysteine	   ligase	   catalytic	   subunit	   (Gclc),	  NAD(P)H:quinone	  oxidoreductase	  1	  
(Nqo1),	   catalase	   (Cat),	   heme	   oxygenase	   1	   (Hmox1),	   multi-­‐drug	   resistance	   protein	   2	   (Mrp2;	  
Abcc2),	  multi-­‐drug	  resistance	  protein	  3	   (Mrp3;	  Abcc3),	  multi-­‐drug	  resistance	  protein	  4	   (Mrp4;	  
Abcc4)	  and	  breast	  cancer	  resistance	  protein	  (Bcrp/Abcg2).	  	  
	   Gclc	  is	  the	  catalytic	  subunit	  for	  Gcl,	  which	  functions	  to	  catalyze	  the	  rate-­‐limiting	  step	  of	  
GSH	   synthesis	   (Gorrini	   et	   al.,	   2013).	   Nqo1	   acts	   in	   the	   reduction	   of	   quinones	   to	   prevent	   the	  
formation	  of	  reactive	  semiquinone	  radicals	  (Atia	  et	  al.,	  2014).	  Cat	  is	  the	  enzyme	  that	  catalyzes	  
the	   conversion	   of	   hydrogen	   peroxide	   to	   water	   and	   oxygen.	   It	   acts	   as	   an	   antioxidant	   by	  
detoxifying	  hydrogen	  peroxide	  and	  preventing	  oxidative	  cellular	  damage	  (Reuter	  et	  al.,	  2010).	  
Hmox1	   is	   involved	   in	   the	   breakdown	   of	   heme	   into	   free	   iron,	  which	   is	   later	   sequestered	   and	  
detoxified	   by	   the	   ferritin	   complex	   (Gorrini	   et	   al.,	   2013).	   Mrp2	   is	   mainly	   expressed	   in	   the	  
hepatocyte	  canalicular	  membrane	  and	  functions	  in	  the	  export	  of	  glucuronate,	  sulfate	  and	  GSH	  
conjugates	   into	  the	  bile	   (Jedlitschky	  et	  al.,	  2006).	  Mrp3	   is	  a	  basolateral	  efflux	  transporter	  and	  
acts	   in	   the	   export	   of	   bile	   acids	   and	   glucuronide	   conjugates	   into	   portal	   circulation	   (Belinsky,	  
2005).	  Mrp4	  is	  a	  basolateral	  efflux	  transporter	  that	  exports	  bile	  acids	  and	  GSH	  conjugates	  into	  
portal	  circulation.	   It	  also	  has	  a	  role	   in	   intracellular	  signaling	  through	  regulation	  of	   intracellular	  
levels	   of	   cyclic	   nucleotides,	   such	   as	   cAMP	   (Russel	   et	   al.,	   2008).	   Bcrp	   is	   a	   canalicular	   efflux	  
transporter	   that	   exports	   endogenous	   compounds,	   such	   as	   urate	   and	   folate,	   and	   many	  
xenobiotics	  into	  the	  bile	  (Eldasher	  et	  al.,	  2013).	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Expression	   of	   Nrf2	  mRNA	  was	   significantly	   increased	   following	   CFB	   treatment	   in	   wild	  
type	  mouse	   liver	   (Figure	  2.5a).	   This	   suggests	   that	  Pparα	  activation	   is	   having	   an	  effect	  on	   the	  
expression	  of	  Nrf2.	  Gclc	  mRNA	  expression	  displays	  significantly	  decreased	  basal	  expression	   in	  
Nrf2-­‐null	  mice,	  compared	  to	  wild	  type.	  Expression	  was	  also	  significantly	  increased	  following	  CFB	  
treatment	   in	  wild	   type	  mice	   (Figure	   2.5b).	   Basal	  mRNA	  expression	   for	  Nqo1	  was	   significantly	  
lower	  in	  Nrf2-­‐null	  mice	  than	  in	  wild	  type.	  Expression	  was	  significantly	   increased	  following	  CFB	  
treatment	  in	  wild	  type,	  but	  not	  in	  Nrf2-­‐null	  mice	  (Figure	  2.5c).	  Basal	  mRNA	  expression	  for	  Cat	  
was	   significantly	   decreased	   in	  Nrf2-­‐null	  mice,	   compared	   to	  wild	   type.	   CFB	   treatment	   had	   no	  
effect	  on	  Cat	  expression	  in	  wild	  type	  or	  Nrf2-­‐null	  mice	  (Figure	  2.5d).	  Furthermore,	  there	  were	  
no	  changes	  in	  Hmox1	  mRNA	  expression	  between	  genotypes	  or	  treatment	  groups	  (Figure	  2.5e).	  
Basal	  expression	  of	  Mrp2	  mRNA	  was	  unchanged	  between	  Nrf2-­‐null	  and	  wild	  type	  mice.	  There	  
was	  a	  trend	  for	  increased	  mRNA	  expression	  following	  CFB	  treatment	  in	  wild	  type	  mice,	  with	  a	  
significant	  increase	  detected	  in	  Nrf2-­‐null	  mice	  (Figure	  2.5f).	  	  
In	   the	   ten	  day	  model	   of	   CFB	  dosing	   (500mg/kg	   i.p.)	  Mrp3,	  Mrp4	  and	  Bcrp	  mRNA	  and	  
protein	  expression	  have	  been	  shown	  to	  increase	  in	  wild	  type	  mouse	  liver	  (Moffit,	  2006).	  In	  the	  
five-­‐day	   model,	   Mrp3	   displayed	   reduced	   basal	   expression	   in	   Nrf2-­‐null	   mice	   and	   increased	  
expression	  following	  CFB	  treatment	  in	  wild	  type	  (Figure	  2.5g).	  There	  was	  no	  significant	  change	  
in	  mRNA	  expression	   for	  Mrp4,	  however	   there	  does	  appear	   to	  be	  a	   trend	   for	  decreased	  basal	  
expression	   in	  Nrf2-­‐null	  mice	   (Figure	   2.5h).	   Basal	   expression	   of	   Bcrp	  was	   reduced	   in	  Nrf2-­‐null	  
mice,	  which	  was	   increased	   to	  wild	   type	  basal	   levels	  of	  expression	   following	  CFB	   treatment	   in	  
Nrf2-­‐null	  mice	  (Figure	  2.5i).	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Figure	  2.5:	  Hepatic	  Gene	  Expression	  of	  Nrf2	  and	  Nrf2–Dependent	  Genes.	  qRT-­‐PCR	  was	  performed	  using	  
cDNA	  isolated	  from	  wild-­‐type	  and	  Nrf2-­‐null	  mouse	  livers	  24	  hours	  after	  the	  last	  of	  five	  daily	  doses	  of	  CFB	  
(250mg/kg;	  i.p.).	  (A)	  Gene	  expression	  of	  Nrf2.	  (B-­‐H)	  Gene	  expression	  of	  Nrf2-­‐dependent	  genes	  involved	  
in	  combating	  oxidative	   stress	   (Gclc,	  Nqo1,	  Cat,	  and	  Hmox1),	   canaclicular	  efflux	   transport	   (Mrp2,	  Bcrp)	  
and	  basolateral	  efflux	  transport	  (Mrp3,	  Mrp4).	  Data	  is	  presented	  as	  mean	  gene	  expression	  ±	  SEM	  (n=4-­‐5	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Altogether	   these	   results	   suggest	   Pparα	   may	   be	   involved	   in	   the	   regulation	   of	  
transcription	  for	  Nrf2	  and	  some	  of	  its	  target	  genes.	  Activation	  of	  Pparα	  by	  CFB	  treatment	  in	  wild	  
type	  mice	  increases	  the	  mRNA	  expression	  of	  Nrf2,	  and,	  as	  already	  demonstrated	  by	  Moffit	  et	  al.	  
(2006,	   2007),	   several	   Nrf2	   target	   genes.	   In	   the	   absence	   of	   Nrf2,	   the	  majority	   of	   Nrf2	   target	  
genes	   tested	   did	   not	   display	   any	   CFB-­‐mediated	   alterations	   to	   expression.	   Following	   CFB	  
treatment,	  however,	  Mrp2	  and	  Bcrp	  displayed	  significant	  increases	  in	  mRNA	  expression	  in	  Nrf2-­‐
null,	   compared	   to	   vehicle-­‐treated	   null	   mice.	   These	   data	   suggest	   that	   Pparα	   activation	   may	  
regulate	  Nrf2	  expression	  and	  may	  play	  a	   role	   in	   the	   transcriptional	   regulation	  of	   several	  Nrf2	  
target	  genes	  in	  the	  absence	  of	  Nrf2.	  	  
	   	  
Loss	  of	  Nrf2	  increases	  mRNA	  expression	  of	  Pgc1α	  in	  mouse	  liver	  
	   Ppar	  gamma	  co-­‐activator	  1-­‐alpha	   (Pgc1α)	   is	  a	  member	  of	   the	  Pgc1	   family	  of	   inducible	  
transcriptional	   co-­‐activators.	   Pgc1	   is	   part	   of	   the	   co-­‐activator	   complex	   that	   directly	   enhances	  
transcription	   initiation	   in	   a	   series	   of	   transcription	   factors,	   including	   both	   nuclear	   and	   non-­‐
nuclear	  receptors,	  involved	  in	  cellular	  metabolism	  (Finck,	  2006).	  Unlike	  in	  muscle	  and	  adipose,	  
Pgc1α	   and	   Pgc1β	   are	   lowly	   expressed	   in	   mouse	   liver.	   During	   a	   period	   of	   fasting,	   however,	  
hepatic	  expression	  of	  Pgc1α	  and	  Pgc1β	   increases.	  During	   fasting,	   FA	  oxidation	   is	   increased	   in	  
the	   liver	   in	  order	  to	  supply	  the	  body	  with	  energy.	  This	   is	  mediated	  through	  Pgc1α	  and	  Pgc1β,	  
which	   function	   as	   co-­‐activators	   for	   Pparα	   and	   act	   to	   increase	   transcription	   of	   Pparα	   target	  
genes	  involved	  in	  FA	  oxidation	  (Lin	  et	  al.,	  2003;	  Yoon	  et	  al.,	  2001).	  In	  hepatocytes	  isolated	  from	  
fasted	  Pgc1α-­‐null	  mice,	  FA	  oxidation	  is	  diminished	  and	  steatosis	  is	  evident	  (Leone	  et	  al.,	  2005).	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This	   suggests	   that	   Pgc1α	   is	   important	   in	   the	   regulation	   of	   hepatic	   FA	   oxidation	   through	   co-­‐
activation	  of	  Pparα.	  
	   Hepatic	  mRNA	  expression	  of	  Pgc1α	  has	  been	  shown	  to	  be	   induced	  following	  fasting	   in	  
both	  Nrf2-­‐null	   and	   C57BL/6	  wild	   type	  mice.	   Compared	   to	   all	   other	   treatment	   groups,	   fasted	  
Nrf2-­‐null	  mice	  displayed	  the	  highest	  levels	  of	  Pgc1α	  expression	  (Zhang	  et	  al.,	  2013).	  In	  another	  
study,	  Sadnerson	  et	  al.	   (2009)	  performed	  ChIP	  analysis	  on	  fasted	  wild	  type	  (129S1/SvImJ)	  and	  
Pparα-­‐null	   mice.	   In	   concordance	   with	   Zhang	   et	   al.	   (2013)	   they	   observed	   increased	   mRNA	  
expression	  of	  Pgc1α	   in	   following	   fasting	   in	  both	  genotypes.	  ChIP	  analysis	  displayed	  enhanced	  
recruitment	  of	   Pgc1α	   to	   the	   transcription	   start	   site	   of	   the	   representative	   Pparα	   target	   genes	  
fatty	   aldehyde	   dehydrogenase	   (Aldh3a2)	   and	   carnitine	   palmitoyltransferase	   2	   (Cpt2)	   in	   wild	  
type	   mice.	   This	   recruitment,	   however,	   was	   not	   present	   in	   Pparα-­‐null	   mice,	   suggesting	   that	  
Pgc1α	  binding	   to	   these	  genes	   is	  Pparα	  dependent	   (Sanderson	  et	  al.,	  2009).	  Analysis	  of	  Pgc1α	  
expression,	   following	   chemical	   activation	   of	   Pparα,	   could	   provide	   insight	   into	   the	   interaction	  
between	  Nrf2	  and	  Pparα.	  This	  is	  because	  increased	  expression	  of	  a	  known	  Pparα	  co-­‐activator,	  
in	  the	  absence	  of	  Nrf2	  expression,	  provides	  a	  possible	  mechanism	  for	  the	  increased	  sensitivity	  
of	  Nrf2-­‐null	  mice	  to	  CFB-­‐mediated	  Pparα	  activation.	  
Analysis	  of	  Pgc1α	  mRNA	  expression	  was	  conducted	  to	  establish	  whether	  or	  not	  CFB	  has	  
any	  effect	  on	  Pgc1α	  expression.	  Basal	  mRNA	  expression	  of	  Pgc1α	  was	  significantly	  increased	  in	  
Nrf2-­‐null	  mice	  compared	  to	  wild	   type.	  Expression	  was	  not	  altered	  by	  CFB	  treatment	   in	  either	  
genotype	  (Figure	  2.6).	  CFB	  acts	  as	  a	  synthetic	  ligand	  for	  Pparα.	  When	  a	  ligand	  binds	  to	  nuclear	  
receptors,	  it	  causes	  disassociation	  of	  the	  co-­‐repressor	  protein	  complex.	  This	  enables	  association	  
of	  co-­‐activator	  proteins,	  which	  then	  act	  to	  enhance	  transcriptional	  initiation	  at	  the	  promoter	  of	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Figure	  2.6:	  Hepatic	  Gene	  Expression	  of	  Pgc1α.	  qRT-­‐PCR	  was	  performed	  using	  cDNA	  isolated	  from	  wild-­‐
type	  and	  Nrf2-­‐null	  mouse	  livers	  24	  hours	  after	  the	  last	  of	  five	  daily	  doses	  of	  CFB	  (250mg/kg;	  i.p.).	  Gene	  
expression	   of	   Pgc1α.	   Data	   is	   presented	   as	   mean	   gene	   expression	   ±	   SEM	   (n=4-­‐5	   mice).	   Values	   with	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target	   genes.	   Increased	   expression	   of	   the	   Pparα	   co-­‐activator	   protein	   Pgc1α	   could	   allow	   for	  
increased	   association	   with	   ligand	   bound	   Pparα	   and	   increased	   transcription	   of	   Pparα	   target	  
genes.	  
	  
Clofibrate	   treatment	   increases	  protein	  expression	  of	  Vanin-­‐1	   in	  wild	   type	  and	  Nrf2-­‐null	  mouse	  
liver	  	  
Western	  blot	  analysis	  of	  Vnn1	  was	  conducted	  to	  determine	   if	   the	  absence	  of	  Nrf2	  has	  
any	   effect	   on	   the	   CFB-­‐mediated	   induction	   of	   protein	   expression	   for	   Pparα	   target	   genes.	  
Expression	  of	  Vnn1	  was	  significantly	  increased	  following	  CFB	  treatment,	  with	  no	  differences	  in	  
the	  magnitude	   of	   induction	   by	   genotype.	   Protein	   expression,	   however,	   was	   not	   significantly	  
different	   between	   CFB-­‐treated	   wild	   type	   and	   Nrf2-­‐null	   mice	   (Figure	   2.7a).	   Further	   protein	  
analysis	  of	  Pparα	  and	  other	  Pparα	  target	  genes	  are	  necessary	  to	  determine	  the	  effect	  of	  CFB	  on	  
Pparα	  activation	  in	  Nrf2-­‐null	  mouse	  liver	  beyond	  our	  gene	  expression	  analysis.	  	  
Analysis	  of	  protein	  expression	   for	   the	  prototypical	  and	   representative	  Nrf2-­‐dependent	  
gene	   Nqo1	   was	   also	   conducted.	   Protein	   expression	   for	   Nqo1	   closely	   resembles	   mRNA	  
expression.	  Expression	  was	  significantly	   increased	  in	  CFB-­‐treated	  wild	  type	  mice,	  compared	  to	  
vehicle-­‐treated	   wild	   type	   mice	   (Figure	   2.7b).	   Nrf2-­‐null	   mice	   demonstrated	   significantly	  
decreased	   basal	   protein	   expression	   of	   Nqo1,	   which	   is	   expected	   since	   Nqo1	   is	   an	   Nrf2-­‐
dependent	   gene.	   CFB-­‐treated	   Nrf2-­‐null	   mice	   displayed	   no	   alterations	   to	   protein	   expression,
compared	  to	  vehicle-­‐treated	  null	  mice.	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Figure	   2.7:	   Hepatic	   protein	   expression	   of	   Vnn1.	   Western	   Blots	   were	   performed	   using	   whole-­‐liver	  
homogenates	   isolated	   from	  wild-­‐type	  and	  Nrf2-­‐null	  mice	  24	  hours	  after	   the	   last	  of	   five	  daily	  doses	  of	  
CFB	   (250mg/kg;	   i.p.).	   (A)	   Protein	   expression	   of	   Vnn1.	   (B)	   Quantitation	   of	   Vnn1	   protein	   expression,	  
normalized	   to	   β-­‐actin.	   (C)	   Protein	   expression	   of	   Nqo1.	   (D)	   Quantitation	   of	   Nqo1	   protein	   expression	  
normalized	   to	   β-­‐actin.	   Data	   is	   presented	   as	   mean	   gene	   expression	   ±	   SEM	   (n=4-­‐5	   mice).	   Values	   with	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Clofibrate	   pretreatment	   may	   partially	   protect	   Nrf2-­‐null	   mice	   against	   Acetaminophen	  
hepatotoxicity	  
	   Pretreatment	   of	   wild	   type	   mice	   with	   the	   fibrate-­‐type	   drug	   CFB	   is	   known	   to	   provide	  
protection	  against	  a	  challenge	  dose	  of	  APAP,	  however,	  the	  protective	  role	  of	  CFB	  has	  not	  been	  
investigated	   in	  Nrf2-­‐null	  mice.	   In	   order	   to	   determine	   if	   CFB	   pretreatment,	   in	   the	   absence	   of	  
Nrf2,	   is	  able	   to	  protect	  against	  a	   toxic	   insult	  of	  APAP,	  Nrf2-­‐null	  mice	  were	  pretreated	   for	   five	  
days	  with	  250mg/kg	  of	  CFB	  and	  challenged	  with	  300mg/kg	  of	  APAP	  on	  day	  six.	  There	  was	  no	  
significant	  change	   in	   the	   liver	   to	  bodyweight	   ratios	  between	  treatment	  groups	  24	  hours	  after	  
APAP	   challenge	   (Figure	   2.8a).	   This	   indicates	   that	   this	   alternative	   CFB	   treatment	   regimen	   of	  
reduced	  dose	  and	  length	  did	  not	  result	  in	  hepatomegaly.	  Compared	  to	  vehicle-­‐treated	  control	  
mice,	   there	  was	   a	   significant	   increase	   in	   ALT	   activity	   in	   vehicle-­‐treated	  mice	   challenged	  with	  
APAP.	  In	  CFB	  pretreated	  Nrf2-­‐null	  mice	  receiving	  APAP,	  ALT	  activity	  was	  also	  increased	  slightly,	  
however,	   these	  values	  were	  not	   significantly	  different	   from	  either	  vehicle	   treated	  controls	  or	  
vehicle-­‐pretreated	  mice	   challenged	  with	   APAP	   (Figure	   2.8b).	   In	   this	   study,	   ALT	   values	   at	   the	  
dose	  of	  APAP	  used	   (300mg/kg)	  are	  much	   lower	   than	  our	  historical	   values.	  This	   indicates	   that	  
the	   APAP	   dose	   in	   the	   current	   study	   did	   not	   produce	   sufficient	   toxicity	   to	   distinguish	   any	  
potential	  differences	  in	  response	  by	  treatment.	  This	  is	  supported	  by	  the	  lack	  of	  any	  histological	  
indications	   of	   hepatotoxicity	   (i.e.	   centrilobular	   necrosis)	   in	   control	   mice	   receiving	   APAP	  
challenge	   (data	   not	   shown).	   A	   significant	   decrease	   in	   liver	   non-­‐protein	   sulfhydryl	   (NPSH)	  
content	  was	  observed	  in	  vehicle-­‐pretreated	  mice	  challenged	  with	  APAP,	  compared	  to	  the	  mice	  
receiving	   CFB	   only.	   Compared	   to	   all	   other	   groups,	   there	   was	   a	   trend	   for	   decreased	   NPSH	  
content	   in	  vehicle-­‐pretreated	  mice	  receiving	  APAP.	  Compared	  to	  all	  other	  groups	  there	  was	  a	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Figure	  2.8:	  Liver	  to	  Bodyweight	  Ratio,	  ALT	  Activity	  and	  Hepatic	  Non-­‐Protein	  Sulfhydryl	  Content	  Following	  
APAP	  challenge.	  Liver	  and	  serum	  was	  isolated	  from	  Nrf2-­‐null	  mouse	  livers	  24	  hours	  after	  APAP	  challenge	  
(300mg/kg;	   50%	   propylene	   glycol,	   i.p.).	   (A)	   Liver	   to	   bodyweight	   ratio	   presented	   as	   percent	   of	   total	  
bodyweight.	   (B)	  ALT	  activity	   (U/L).	   (C)	  Hepatic	  NPSH	  content	  presented	  as	  μmol	  of	  NPSH	  per	   gram	  of	  
liver.	  Data	  is	  presented	  as	  mean	  gene	  expression	  ±	  SEM	  (n=3-­‐5	  mice).	  Values	  with	  different	  superscripts	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trend	   for	   increased	   NPSH	   content	   in	   mice	   receiving	   only	   CFB	   (Figure	   2.8c).	   Similarly,	   NPSH	  
content	  was	  higher	  in	  CFB	  pretreated	  mice	  than	  in	  vehicle	  control	  or	  vehicle-­‐pretreated	  mice.	  
However,	   this	   elevation	   in	   NPSH	   was	   not	   significantly	   different	   from	   any	   other	   treatment	  
groups.	   This	   suggests	   that	   CFB	   pretreated	   Nrf2-­‐null	   mice	   may	   be	   less	   susceptible	   to	   GSH	  
depletion	  following	  a	  toxic	  insult	  of	  APAP.	  	  
	  
2.5	  Discussion:	  
The	  Nrf2	  and	  Pparα	  transcription	  factors	  have	  both	  been	  demonstrated	  to	  play	  a	  role	  in	  
protection	  against	  APAP-­‐induced	  hepatotoxicity	  (Goldring	  et	  al.,	  2004;	  Nicholls-­‐Grzemski	  et	  al.,	  
1992).	  The	  dependence	  of	  Pparγ	  action	  on	  Nrf2	  signaling	  has	  been	  demonstrated	   in	   lung	  and	  
adipose	   tissue,	  and	  appears	   to	  act	   through	  binding	  of	  Nrf2	   to	  an	  ARE	   in	   the	  Pparγ	  promoter.	  
The	  importance	  of	  this	  regulation	  was	  demonstrated	  in	  Nrf2-­‐null	  mice,	  which	  display	  decreased	  
basal	   expression	   of	   Pparγ,	   increased	   susceptibility	   to	   acute	   lung	   injury,	   and	   impaired	  
adipogenesis	   (Cho	   et	   al.,	   2010;	   Pi	   et	   al.,	   2010).	   Positive	   regulation	   of	   the	   Ppar	   heterodimer	  
partner,	   Rxrα,	   through	  Nrf2	  binding	   to	   an	  ARE	   in	   the	  promoter	  has	   also	  been	   shown	   in	   vitro	  
(Chorley	   et	   al.,	   2012).	   Despite	   some	   experimental	   evidence	   supporting	   an	   interaction,	   a	  
regulatory	  link	  between	  Nrf2	  and	  Pparα	  is	  yet	  to	  be	  established.	  	  
In	  the	  present	  study,	  the	  increased	  susceptibility	  of	  Nrf2-­‐null	  mice	  to	  Pparα	  activation,	  
by	  means	  of	  CFB	  treatment,	  was	  demonstrated.	  Vehicle-­‐treated	  Nrf2-­‐null	  mice	  had	  a	  decreased	  
liver	   to	   bodyweight	   ratio	   compared	   to	   vehicle-­‐treated	  wild	   type	  mice.	   This	   decrease	   did	   not	  
occur	  in	  CFB-­‐treated	  Nrf2-­‐null	  mice.	  There	  was	  also	  no	  change	  in	  the	  liver	  to	  bodyweight	  ratio	  
of	  CFB-­‐treated	  wild	  type	  mice.	  In	  the	  literature,	  500mg/kg	  CFB	  treatment	  for	  ten	  days	  has	  been	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reported	   to	   cause	   hepatomegaly	   in	   wild	   type	   mice	   (Manautou	   et	   al.,	   1994).	   Due	   to	   this	  
treatment	  regimen	  being	  toxic	  in	  Nrf2-­‐null	  mice,	  a	  new	  regimen	  of	  CFB	  dosing	  at	  250mg/kg	  for	  
five	  days	  was	  implemented.	  In	  the	  present	  study,	  the	  new	  treatment	  model	  was	  not	  sufficient	  
to	  produce	  hepatomegaly	  in	  wild	  type	  or	  Nrf2-­‐null	  mice;	  however,	  it	  was	  sufficient	  to	  cause	  an	  
increase	   in	   the	   liver	   to	  bodyweight	   ratio	  of	  CFB-­‐treated	  Nrf2-­‐null	  mice,	   compared	   to	   vehicle-­‐
treated	  Nrf2-­‐null	  mice.	  No	  evidence	  for	  hepatotoxicity	  was	  noted	  and	  animal	  viability	  was	  not	  
compromised.	  
CFB	   is	   a	   member	   of	   the	   fibrate-­‐type	   class	   of	   hypolipidermic	   drugs	   that	   act	   through	  
activation	   of	   the	   Pparα	   signaling	   pathway	   (Chen	   et	   al.,	   2000).	   In	   the	   present	   study,	   mRNA	  
expression	   of	   Pparα	   was	   significantly	   elevated	   in	   Nrf2-­‐null	   mice	   following	   CFB	   treatment.	  
Analysis	  of	  mRNA	  expression	  for	  Pparα-­‐dependent	  genes	  revealed	  a	  pattern	  of	  increased	  mRNA	  
expression	  for	  both	  wild	  type	  and	  Nrf2-­‐null	  mice	  treated	  with	  CFB.	  A	  greater	  fold	  change	  was	  
observed	  in	  Nrf2-­‐null	  mice.	  These	  findings	  suggest	  that	  Nrf2-­‐null	  mice	  exhibit	  a	  greater	  increase	  
in	  Pparα	  activation	  by	  CFB	   than	  wild	   type	  mice.	  Western	  blot	  analysis	  of	  Vnn1	  demonstrated	  
significantly	  increased	  protein	  expression	  following	  CFB	  treatment	  in	  both	  wild	  type	  and	  Nrf2-­‐
null	  mice.	  Protein	  expression,	  however,	  did	  not	  significantly	  differ	  between	  the	  two	  genotypes	  
following	  CFB	  treatment.	  This	  indicates	  that	  induction	  of	  Vnn1	  protein	  by	  CFB	  is	  not	  influenced	  
by	  Nrf2	  expression	  or	  function,	  at	  least	  not	  with	  this	  regimen	  of	  CFB	  treatment.	  Further	  protein	  
analysis	   of	   Pparα	   and	   other	   target	   genes,	   such	   as	   Acox1,	   Pdk4	   and	   Cyp4a10,	   are	   needed	   to	  
determine	   if	   the	   data	   obtained	   from	  mRNA	   analysis	   is	   corroborated	   by	   data	   obtained	   from	  
protein	  analysis.	  This	  would	  provide	  a	  better	  understanding	  as	  to	  the	  effect	  of	  CFB	  treatment	  
on	  Pparα	  activation	  in	  Nrf2-­‐null	  mouse	  liver.	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   The	  Ppar	   family	  of	   transcription	   factors	   consists	  of	   three	  members	   (Pparα,	  Pparγ,	  and	  
Pparβ/δ),	  which	  are	  differentially	  expressed	  throughout	  the	  body.	  Pparγ	  is	  mainly	  expressed	  in	  
adipose	   tissue	   (Zieleniak	   et	   al.,	   2008).	   Interactions	   between	   Nrf2	   and	   Pparγ	   are	   present	   in	  
mouse	  adipose	  and	   lung	   tissue,	  but	   this	  has	  not	  been	  studied	   in	   the	  mouse	   liver.	  Our	   results	  
show	  that	  Pparγ	  mRNA	  expression	  in	  the	  mouse	  liver	  was	  not	  affected	  by	  CFB	  treatment,	  but	  
was	   significantly	   decreased	   in	   vehicle-­‐treated	   Nrf2-­‐null	   compared	   to	   wild	   type	   mice.	   This	   is	  
consistent	  with	  previous	  reports	  examining	  mouse	  lung	  and	  adipose	  tissue	  (Cho	  et	  al.,	  2010;	  Pi	  
et	  al.,	  2010).	  Analysis	  of	  Pparγ	  protein	  expression	  is	  still	  required,	  but	  Pparγ	  mRNA	  expression	  
suggests	   that	  Nrf2	  may	  be	  a	  positive	  regulator	  of	  Pparγ	   in	   the	  mouse	   liver.	  Analysis	  of	  mRNA	  
expression	   for	   some	   Pparγ	   target	   genes	   displayed	   no	   significant	   change	   following	   CFB	  
treatment	   in	   wild	   type	   mice.	   Expression	   of	   these	   genes	   in	   Nrf2-­‐null	   mice,	   however,	   was	  
significantly	   increased	   by	   CFB	   treatment.	   It	   appears	   that	   in	   the	   mouse	   liver	   Pparα	  
predominantly	  regulates	  these	  selected	  Pparγ	  target	  genes.	  This	  is	  not	  surprising	  because	  Pparγ	  
and	  Pparα	  have	  both	  been	  demonstrated	  to	  regulate	  a	  set	  of	  overlapping	  genes	  involved	  in	  lipid	  
metabolism	   (i.e.	   Lpl,	   Fabp4)	   (Nakachi	   et	   al.,	   2008;	   Rakhshandehroo	   et	   al.,	   2010).	   Also,	   Pparγ	  
acts	   mainly	   in	   adipose	   tissue	   as	   a	   regulator	   of	   lipid	   and	   glucose	   metabolism,	   and	   is	   only	  
expressed	  at	   low	   levels	   in	   the	   liver.	  Pparα,	  on	  the	  other	  hand,	   is	  highly	  expressed	   in	   the	   liver	  
and	   acts	   as	   a	  main	   regulator	   of	   hepatic	   lipid	  metabolism	   (Tyagi	   et	   al.,	   2011).	   These	   findings	  
suggest	   that,	  when	  analyzed	   in	   the	   liver,	   these	   selected	  Pparγ	   target	   genes	   (i.e.	   Slc27a1,	   Lpl,	  
Fabp4,	  Glut4)	  serve	  as	  better	  indicators	  of	  Pparα	  activity	  than	  as	  indicators	  of	  Pparγ	  activity.	  	  
	   Rxrα	  is	  a	  member	  of	  the	  Rxr	  family	  of	  transcription	  factors	  with	  high	  levels	  of	  expression	  
in	  the	  liver	  (Pérez	  et	  al.,	  2012).	  It	  acts	  as	  a	  heterodimer	  partner	  for	  many	  transcription	  factors	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and	   is	   required	   for	   Pparα	   action.	   Our	   data	   show	   that	   Rxrα	   mRNA	   expression	   is	   not	   altered	  
between	  mouse	  genotypes	  or	  treatment	  group,	  indicating	  that	  Rxrα	  expression	  is	  not	  affected	  
by	   Nrf2	   expression	   or	   function.	   This	   finding	   is	   contradictory	   to	   previous	   reports	   that	   mRNA	  
expression	   of	   Rxrα	   is	   decreased	   by	   knocking	   down	  Nrf2	   function	   (Chorley	   et	   al.,	   2012).	   This	  
apparent	  discrepancy	  may	  be	  due	   to	  differences	   in	  experimental	  models.	  Our	   study	  analyzed	  
mRNA	  expression	  of	   Rxrα	   in	   vivo,	   using	  wild	   type	   and	  Nrf2-­‐null	  mice,	  whereas	   Chorley	   et	   al.	  
(2012)	  analyzed	  mRNA	  expression	  in	  vitro,	  using	  shRNA	  knockdown	  of	  Nrf2	  in	  mouse	  embryonic	  
fibroblasts.	  	  
Analysis	  of	  mRNA	  expression	   for	  all	  of	   the	  Rxrα	  target	  genes	   tested	  revealed	  that	  CFB	  
treatment	   had	   no	   effect	   on	   expression.	   Two	   of	   the	   analyzed	   target	   genes,	   mainly	   Dio1	   and	  
Rbp1,	  displayed	  altered	  basal	  mRNA	  expression	  in	  Nrf2-­‐null	  compared	  to	  wild	  type	  mouse	  liver.	  
Basal	  expression	  of	  Dio1	  was	   significantly	  decreased	   in	  Nrf2-­‐null	   compared	   to	  wild	   type	  mice	  
and	  the	  basal	  expression	  of	  Rbp1	  was	  significantly	  increased	  in	  Nrf2-­‐null	  compared	  to	  wild	  type	  
mice.	  Other	  target	  genes	  (i.e	  Rarα,	  Cyp2r1),	  however,	  displayed	  no	  change	  in	  basal	  expression	  
between	  genotypes.	  The	  cause	  of	  the	  Nrf2-­‐dependent	  changes	  in	  basal	  expression	  of	  Dio1	  and	  
Rbp1	  are	  not	  clear,	  but	  it	  seems	  that	  the	  changes	  are	  not	  mediated	  by	  Rxrα	  signaling.	  	  	  
CFB	  has	  been	  previously	  reported	  to	   increase	  protein	  and	  mRNA	  expression	  of	  several	  
Nrf2	   target	   genes,	   including	   Mrp3,	   Mrp4	   and	   Bcrp	   (Moffit,	   2006).	   Interestingly,	   mRNA	  
expression	  of	  Nrf2	  was	  increased	  in	  wild	  type	  mice	  following	  CFB	  treatment.	  Protein	  expression	  
is	  required	  to	  confirm	  this	  finding.	  As	  previously	  demonstrated	  by	  Moffit	  et	  al.	  (2006,	  2007)	  CFB	  
treatment	  caused	  increases	  in	  mRNA	  expression	  for	  the	  Nrf2	  target	  genes	  Gclc,	  Nqo1	  and	  Mrp3	  
in	  wild	  type	  mouse	  liver.	  Protein	  expression	  for	  Nqo1	  was	  also	  increased	  in	  wild	  type	  following	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CFB	  treatment.	  With	  the	  exception	  of	  Mrp2	  and	  Bcrp,	  the	  majority	  of	  Nrf2	  target	  genes	  tested,	  
did	  not	  display	  any	  CFB-­‐mediated	  alterations	   to	  expression	   in	   the	  absence	  of	  Nrf2.	  Mrp2	  and	  
Bcrp,	   however,	   displayed	   significant	   increases	   in	   mRNA	   expression	   in	   CFB-­‐treated	   Nrf2-­‐null,	  
compared	  to	  vehicle-­‐treated	  null	  mice.	  Furthermore,	  mRNA	  expression	  for	  Nrf2	  was	  elevated	  in	  
CFB-­‐treated	  wild	  type	  mice	  compared	  to	  vehicle-­‐treated	  controls.	  Peroxisome	  proliferators	  are	  
known	   to	   cause	   oxidative	   stress	   in	   rodents	   thorough	   the	   indirect	   production	   of	   hydrogen	  
peroxide	  (Gonzalez	  and	  Shah,	  2008).	  The	  observed	  increases	  in	  Nrf2	  mRNA	  expression	  may	  thus	  
be	   a	   direct	   result	   of	   CFB	   dosing.	   Further	   studies	   of	  Nrf2	   expression	   in	   the	   absence	   of	   Pparα	  
activity	  are	  required	  to	  confirm	  this.	  Altogether,	  these	  data	  suggest	  Pparα	  activation	  may	  play	  a	  
role	   in	   the	   regulation	   of	   Nrf2	   expression	   and	   in	   the	   transcriptional	   regulation	   of	   some	   Nrf2	  
target	  genes	  in	  an	  Nrf2-­‐independent	  manner.	  
	   Once	   the	   Pparα-­‐Rxrα	   heterodimer	   is	   ligand	   bound	   it	   is	   able	   to	   associate	   with	   co-­‐
activator	  proteins.	  Co-­‐activator	  proteins,	  such	  as	  Pgc1α,	   increase	  transcription	  of	  target	  genes	  
by	   interacting	   with	   histone	   acetyltransferases,	   which	   act	   to	   remodel	   chromatin	   so	   that	   the	  
transcriptional	  machinery	  has	   improved	  access	   to	   the	  target	  gene	   (Finck,	  2006).	  Pgc1α	  mRNA	  
and	  protein	  expression	  have	  been	  demonstrated	  to	  increase	  in	  livers	  from	  24	  hour	  fasted	  rats	  
and	  mice	  (Yoon	  et	  al.,	  2001;	  Zhang	  et	  al.,	  2013).	  Fasting	  is	  a	  natural	  way	  of	  indirectly	  activating	  
Pparα.	  Fasting	  causes	  increased	  production	  of	  FAs,	  which	  act	  as	  ligands	  for	  activation	  of	  Pparα	  
(Bouwens	   et	   al.,	   2007).	   CFB,	   on	   the	   other	   hand,	   is	   a	   synthetic	   ligand	   for	   the	   Pparα	   nuclear	  
receptor	   and	   acts	   to	   directly	   activate	   Pparα,	   thus	   inducing	   transcription	   of	   Pparα-­‐dependent	  
genes	   involved	   in	   FA	   oxidation.	   Analysis	   of	   Pgc1α	   mRNA	   expression	   following	   five-­‐day	   CFB	  
treatment	   (250mg/kg)	   revealed	   that	   its	   basal	   expression	   is	   elevated	   in	   Nrf2-­‐null	   mice,	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compared	   to	   wild	   type	   mice.	   Increased	   expression	   could	   explain	   the	   observed	   sensitivity	   of	  
Nrf2-­‐null	  mice	  to	  Pparα	  activation.	  Since	  Pgc1α	  is	  also	  a	  known	  co-­‐activator	  of	  Pparα	  (Barberá	  
et	  al.,	  2001),	  increased	  expression	  of	  Pgc1α	  in	  Nrf2-­‐null	  mice	  suggests	  that	  these	  mice	  may	  have	  
increased	   ligand-­‐mediated	   activation	   of	   Pparα.	   Recruitment	   of	   Pgc1α	   to	   the	   Pparα	  
heterodimer,	   following	   ligand	   binding,	   would	   induce	   transcription	   of	   Pparα	   target	   genes,	   as	  
depicted	  in	  Figure	  2.9.	  Protein	  expression	  of	  Pgc1α	  would	  provide	  further	  insight	  into	  the	  effect	  
of	   loss	  of	  Nrf2	   function	  on	  Pgc1α	  expression	  and	  could	  provide	  a	  possible	  mechanism	  for	  the	  
apparent	  interaction	  between	  Nrf2	  and	  Pparα.	  	  
	   A	   follow-­‐up	   study	   was	   performed	   that	   involved	   challenging	   CFB-­‐pretreated	   Nrf2-­‐null	  
mice	  with	   a	   toxic	   dose	  of	  APAP.	   This	  was	  performed	   to	  determine	   if	   the	  protective	   effect	   of	  
Pparα	  activation	  against	  APAP	  hepatotoxicity	  is	  still	  present	  in	  the	  absence	  of	  Nrf2.	  A	  challenge	  
dose	  of	  300mg/kg	  (50%	  propylene	  glycol;	   i.p.)	  was	  selected	  due	  to	  the	  increased	  sensitivity	  of	  
Nrf2-­‐null	  mice	  to	  APAP.	  Analysis	  of	  serum	  ALT	  levels	  revealed	  that,	  compared	  to	  vehicle-­‐treated	  
control	  mice,	  there	  was	  a	  significant	  increase	  in	  ALT	  activity	  in	  vehicle-­‐treated	  mice	  challenged	  
with	   APAP.	   ALT	   activity	   was	   also	   increased	   slightly	   in	   CFB	   pretreated	   mice,	   however,	   these	  
values	  were	  not	  significantly	  different	  from	  either	  vehicle	  treated	  control	  or	  vehicle-­‐pretreated	  
mice.	  The	  observed	  ALT	  levels	  at	  the	  dose	  employed,	  however,	  do	  not	  match	  our	  historical	  data	  
from	  previous	  APAP	  toxicity	  studies.	  This	  indicates	  that	  the	  APAP	  dose	  of	  300mg/kg	  used	  in	  the	  
present	   study	   was	   not	   sufficient	   to	   produce	   enough	   hepatotoxicity	   in	   Nrf2-­‐null	   mice	   to	  
distinguish	   potential	   differences	   in	   response	   by	   treatment.	   Although	   this	   dose	   should	   have	  
produced	   noticeable	   toxicity	   in	   Nrf2-­‐null	   mice	   our	   historical	   experience	   with	   APAP	   toxicity	  
studies	  has	  demonstrated	  that	  seasonal	  variations	  (i.e.	  time	  of	  year)	  in	  responsiveness	  to	  APAP
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  Figure	  2.9:	  Potential	  mechanism	  for	   increased	  activation	  of	  Pparα	  in	  Nrf2-­‐null	  mice.	  Depicts	  activation	  
and	   nuclear	   translocation	   of	   Nrf2	   in	   the	   presence	   of	   oxidative	   stress,	   as	   well	   as	   activation	   of	   Pparα	  
through	   ligand	  binding,	   co-­‐repressor	  dissociation	  and	  co-­‐activator	  association.	   Increased	  expression	  of	  
Pgc1α	  observed	  in	  the	  absence	  of	  Nrf2	  may	  result	  in	  increased	  ligand-­‐dependent	  recruitment	  of	  Pgc1α	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toxication	  can	  be	  prominent.	  Analysis	  of	  hepatic	  NPSH	  content	  revealed	  a	  trend	  for	   increased	  
basal	   levels	   of	   GSH	   in	   CFB-­‐treated,	   compared	   to	   vehicle-­‐treated	   Nrf2-­‐null	   mice.	   This	   is	  
consistent	  with	  studies	  of	  repeated	  CFB	  dosing	  in	  wild	  type	  mice	  (Manautou	  et	  al.,	  1994).	  There	  
was	   also	   a	   trend	   for	   decreased	   GSH	   restoration	   in	   vehicle-­‐pretreated,	   compared	   to	   CFB-­‐
pretreated,	  APAP	  challenge	  groups.	  This	   indirectly	  suggests	  that	  higher	  GSH	  content	  following	  
CFB	   pretreatment,	   even	   in	   the	   absence	   of	   Nrf2,	   may	   have	   the	   potential	   to	   partially	   protect	  
against	  oxidative	  stress,	  such	  as	  that	  produced	  by	  APAP’s	  reactive	  intermediate.	  
	  
2.6	  Conclusion:	  
	   The	  present	  study	  indicates	  that	  Nrf2	  and	  Pparα	  interact	  in	  a	  way	  that	  most	  likely	  does	  
not	  require	  direct	  binding	  between	  the	  two	  transcription	  factors.	  Further	  studies	  are	  required	  
to	  determine	  the	  exact	  mechanism	  of	  this	  interaction,	  however,	  it	  appears	  that	  the	  mechanism	  
may	   involve	   regulation	   of	   the	   co-­‐activator	   protein	   Pgc1α.	   ChIP	   analysis	   could	   be	   utilized	   to	  
determine	   the	   level	   of	   Pgc1α	   being	   recruited	   to	   the	   transcription	   start	   site	   of	   Pparα	   target	  
genes	   in	   vehicle-­‐	   and	   CFB-­‐treated	   wild	   type	   and	   Nrf2-­‐null	   mouse	   livers.	   This	   would	   provide	  
insight	  as	  to	  whether	  or	  not	  Pgc1α	  plays	  a	  role	  for	  the	  increased	  sensitivity	  of	  Nrf2-­‐null	  mice	  to	  
Pparα	  activation.	  
Further	   studies	   on	   the	   induction	   of	   Nrf2	   expression	   following	   CFB	   treatment	   could	  
provide	   additional	   insight	   into	   the	   interaction	   between	  Nrf2	   and	   Pparα.	   These	   studies	   could	  
include	  protein	  analysis	  of	  Nrf2	  following	  CFB	  pretreatment	  in	  wild	  type	  mice.	  Also,	  analysis	  of	  
Nrf2	  mRNA	  and	  protein	  expression	  could	  be	  conducted	   in	  vehicle	  and	  CFB-­‐treated	  Pparα-­‐null	  
mice	  to	  determine	  if	  the	  observed	  increase	  in	  Nrf2	  mRNA	  expression	  following	  CFB	  treatment	  is	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Pparα	  dependent.	  This	  study	  may	  also	  benefit	  from	  extending	  CFB	  treatment	  (250mg/kg)	  from	  
five	  days	  to	  ten	  days.	  It	  has	  been	  established	  that	  Nrf2-­‐null	  mice	  can	  tolerate	  250mg/kg	  of	  CFB	  
for	  five	  days.	  Extending	  treatment	  to	  ten	  days	  may	  further	  induce	  the	  observed	  CFB-­‐mediated	  
activation	  of	  Pparα	  in	  both	  wild	  type	  and	  Nrf2-­‐null	  mice.	  It	  is	  also	  possible	  that	  extending	  CFB	  
treatment	  to	  ten	  days	  may	  be	  sufficient	  to	  produce	  hepatomegaly,	  which	  was	  observed	  in	  the	  
ten	  day,	  500mg/kg	  model	  of	  CFB	  dosing.	  It	  is	  also	  possible	  that	  protein	  expression	  of	  Vnn1	  may	  
better	  reflect	  the	  observed	  mRNA	  expression	  if	  CFB	  treatment	  was	  extended.	  	  
Developing	  a	  mechanism	  for	  the	   interaction	  between	  Nrf2	  and	  Pparα	  would	  provide	  a	  
better	  understanding	  of	  APAP-­‐induced	  liver	  injury	  and	  may	  result	  in	  improved	  understanding	  of	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